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Abstract 
 
Introduction Sickle cell trait carriers may experience sickling events, which can cause 
severe health problems.  Some sickle cell haplotypes contain genetic modifiers that 
are associated with increased levels of fetal hemoglobin, which is resistant to sickling. 
The aim of this study is to determine if sickle cell trait individuals who do not carry 
these modifiers are more likely to experience sickling episodes than those who do 
carry the modifiers. 
Methods Participants were eligible for inclusion in this study if they were male, 18 
years of age or older, a sickle cell trait carrier, and had previously played any level of 
organized football.  Participants were recruited via Facebook, www.clinicaltrials.gov, 
e-mail, phone calls, and word of mouth.  They were asked to complete a survey and 
return a buccal swab for genetic analysis to look for alleles associated with fetal 
hemoglobin persistence.  To date, no genetic analyses have been run.  Data from the 
surveys was analyzed using Fisher’s Exact Test with the SAS 9.2 software.   
Results Twenty participants were included in this phase of the study and all returned 
both the survey and buccal swab.  Five of the 20 participants had been diagnosed with 
exertional sickling, 2 with heat illness, and 12 had experienced dehydration. 
Conclusion Data in this study is purely observational, as no genetic analyses have been 
performed at this point.  Early results indicate that the probability a player feels their 
muscle pain lasts longer than their peers’ is greater among those who feel it takes 
their muscles longer to recover than their peers’.
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Introduction 
 
Sickle cell trait (Hb AS) is a hemoglobinopathy resulting from the sickle cell 
mutation.  Sickle cell trait individuals inherit 1 A allele and 1 S allele and are often 
referred to as Hb AS carriers; 8% - 9% of the U.S. population are Hb AS carriers.  Those 
with sickle cell disease inherit 2 sickle cell genes.  Sickle cell trait carriers usually live 
a life free of the clinical problems associated with sickle cell disease.  However, 
recent news reports point out that a number of sickle cell carrier athletes have 
unexpectedly died due to sickle cell crises.  These articles note that there have been 
22 sickle cell trait related deaths in athletes in the United States between 1980 and 
2009; specifically, 18 deaths occurred among football players, 3 among basketball 
players, and 1 in a track athlete (Elseveth, 2013; George 2011; O'Connor et al., 2012).  
All abbreviations used throughout this paper can be found in Appendix 1.  
 Sickle Cell Anemia (Hb SS or Hb SS) is a severe disorder caused by the 
inheritance of 2 sickle cell genes.  These individuals are referred to as sickle cell 
disease sufferers or homozygotes.  In the United States (U.S.) alone approximately 
72,000 people suffer from Hb SS (Anonymous, 2005).  Research has had limited 
success in creating treatments to enhance quality of life for those suffering from Hb 
SS, though palliative methods have been used during the last 100 years (Wailoo & 
Pemberton, 2006).  Recent advancements in medical care have increased life 
expectancy for individuals with Hb SS, including the discovery of the effects of fetal 
hemoglobin, which is perhaps the most important modifier of the clinical presentation 
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of Hb SS.  Treatments that induce production of fetal hemoglobin (Hb F) show 
potential for preventive care and improved quality of life, though mechanisms 
underlying this approach are complex and require further investigation. 
Sickle Cell Anemia: Environmental change and natural selection 
The evolution of high frequencies of hemoglobin S is an area of study that benefits 
from a biocultural approach.  The biocultural synthesis has looked beyond genetic 
evolution to identify possible causes for the spread and selection of the sickle cell 
gene as well as the factors behind the selective pressure.  In 1976, Frank B. 
Livingstone succinctly wrote, “The simulation of clinal variation for the hemoglobin… 
show the kinds of ethnological, archeological, and demographic data that need to be 
collected to advance our understanding of human genetic change.”   
 In 1949, Haldane proposed that heterozygotes for certain hemoglobinopathies 
were protected against malaria.  In particular, he mentions the protective qualities of 
alpha-thalassemia.  Other early papers discuss lower infection rates in Hb AS 
individuals and “sicklers”.  Shortly thereafter, in the late 1950’s, Livingstone argued 
that Hb S was found in higher frequencies in populations who had adopted agricultural 
practices as opposed to those living in forested areas and who were hunters and 
gatherers.  He concluded that the spread of Hb S mirrored the spread of agriculture 
due to commonly practiced slash and burn methods to clear areas in order to create 
fields.  These methods affected the environment in myriad ways.  The loss of trees 
not only served to increase the amount of sunlight reaching the ground, but also 
cleared away the humus created by the trees.  The humus caused the soil to absorb 
water from frequent rainfalls quickly and efficiently; the lack of the humus caused 
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the ground to dry and harden, which in turn created standing pools of water from 
rainfall.  Standing pools of water and adequate sunlight are 2 of the requirements for 
the growth of Anopheles gambiae, the mosquito vector for Plasmodium falciparum.  
Thus, the adoption of agriculture led to an increase in the mosquito population and an 
increase in malarial infection.  Furthermore, Livingstone notes that spread of 
agriculture caused a population boom and humans became the most available source 
of food for the Anopheles gambiae.  The increase in mosquitoes as well as humans 
allowed malaria to spread until it ultimately reached hyperendemicity (Gong et al., 
2013; Livingstone, 1958; Livingstone, 1971; Livingstone, 1976; Weisenberg, 1967).   
 Though the exact mechanism of protection is unclear, the sickle mutation has 
been found to be protective against malaria in trait form.  Due to this protection, 
selective pressures likely caused an increased prevalence of the sickle mutation in 
areas with historically endemic malaria.  Erythrocytes infected with malaria may 
sickle more readily, leading to increased phagocytosis of infected cells.  The sickle 
mutation may also cause red blood cells to present substances on the cell surface that 
bind to foreign substances, again resulting in increased phagocytosis of the Hb S cells.  
Additionally, it has been proposed that conditions within the Hb S erythrocyte are 
inhospitable to malarial infection, which can lead to reduced infection rates (Gong et 
al., 2013; Livingstone, 1971).  Sickle cell trait carriers (Hb AS) are at a greater 
advantage for malaria protection with a reduced likelihood of poor clinical outcomes 
due to sickling.   Unfortunately, Hb SS individuals may not see this protection and 
usually suffer from poor health and shortened lifespans due to their condition.  On 
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average, women with Hb SS live to be approximately 48 years old, while men live to 
be about 42 years old (Platt et al., 1994). 
 Normal adult hemoglobin consists of 2 alpha chains and 2 beta chains.  The 2 
alpha chains are identical to each other and the 2 beta chains are also identical to 
each other.  The alpha and beta chains combine to carry a heme, which is a 
nonprotein molecule that contains iron, which allows it to carry and oxygen molecule.  
In most normal adult and Hb F the alpha chains are identical and the hemoglobin 
differs by the second chain (ie. the gamma chain in place of the beta chain in Hb F).  
The allele that codes for the alpha chain is found at a high frequency in many 
populations and thus genotype AA is considered “normal” adult hemoglobin (Hb AA).   
 The sickle cell mutation is the result of a base substitution on the hemoglobin 
beta chain.  The shift occurs when a glutamine is replaced by a valine at the sixth 
position on gene, which is found in the eleventh chromosome (Powars & Hiti, 1993; 
Maier-Redelsperger, 1998).  This mutation causes the red blood cell to become 
hydrophobic and under certain conditions the cell will polymerize and become rigid.  
They usually last from 3 to 7 days, but can continue for months (Yale et al. 2000).  
The tissue and organ complications caused by VOCs contribute to the shortened 
lifespan expected in those with Hb SS.  Once the cell has collapsed it looks like a 
sickle, which is where the name sickle cell anemia originates.  It is largely accepted 
that at least five beta globin mutations arose in separate events and which were 
chosen by natural selection in response to malaria.  To date, 31 variations of the beta 
gene have been found worldwide.  These mutations have been divided into five 
haplotypes based on the restriction fragment length polymorphisms (RFLP) 
	  	   5	  
surrounding the beta gene and named for the location where they were first 
discovered.  The haplotype groupings are: Senegal, Benin, Central African Republic 
(CAR) (also known as Bantu (Neonato et al., 2000)), Indian/Arab (also known as Saudi 
Arabia/India), and Cameroon (occasionally identified as Asia).  The three most 
common haplotypes in the United States and South America are CAR, Senegal, and 
Benin (Adekile et al., 2007; Mielke et al.; 2011; Powars & Hiti, 1993; Sheehan et al., 
2013).   
Clinical Presentation 
In 1910, Dr. James Herrick was the first to describe the medical condition that 
came to be known as Hb SS (Pemberton, 2006).  In 1904, a young man from Grenada 
requested treatment from Dr. Herrick for his symptoms, which included a cough, 
fever, jaundice, dizziness, weakness, anemia, chest complications, and a history of 
leg ulcers.  Dr. Herrick found that his blood contained a “large number of thin, 
elongated, sickle-shape and crescent-shaped forms” (Herrick, 1910). While American 
doctors were largely unaware of the condition that came to be known as Hb SS, it 
appears that many West Africans knew of its existence and could accurately describe 
the symptoms.  Africanus Horton provided the first written evidence of Hb SS in Africa 
in 1874, 36 years before Herrick named the condition (Anionwu & Atkin, 2001).   
Acute chest syndrome (ACS) is a significant clinical complication of Hb SS and is 
the leading cause of death among Hb SS patients.  The etiology of ACS is unclear and 
presentation is complex.  It involves pleural effusion, fever, cough, multiple lobe 
involvement, leukocytosis, pleuritic chest pain, crackling noises when listening to the 
lungs, and infiltrates visible in chest x-rays (Vichinsky et al., 2000; Paul et al., 2011; 
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Castro et al., 1994).  Vichinsky et al. (2000) found that 72% of patients who were 
found to have ACS were originally admitted to the hospital for a vaso-occlusive crisis 
(VOC).  It is thought that ACS episodes are precipitated by a VOC, asthma, infection, 
and fat embolism (Vichinsky et al., 2000; Buchanan et al, 2005; Paul et al., 2011).  
Infection and fat embolism are the 2 most common causes of ACS; 1 study found that 
30% of ACS cases were precipitated by bacterial infection (Paul et al., 2011). 
Infection plays a significant role in sickle cell crises, especially in children.  
Between 6 months and 3 years of age normal spleen function virtually disappears in 
Hb SS children due to repeated splenic infarctions that cause the organ to shrink and 
in some cases to completely cease functioning.  Since the spleen can no longer 
effectively filter blood the Hb SS individual is more susceptible to developing 
infection and then sepsis, which can lead to a rapid death.  Due to the potential for 
health problems including bone and tissue infarction and an increased risk for 
hospitalization, Hb SS people are more susceptible to infection:  bone infarction can 
create areas of bone that harbor bacteria, tissue infarction in the bowel may allow 
bacteria to enter the blood stream, and upper respiratory infections can end in an 
episode of ACS.  Interestingly, 2 studies found that salmonella, a relatively common 
food-borne pathogen, is the root cause for almost half of the cases of acute 
osteomyelitis in Hb SS individuals.  Furthermore, those who have been taking 
antibiotics intravenously for extended periods of time are also more likely to develop 
infections in hospital settings, particularly at catheter sites (Booth et al., 2010; Stacy 
et al., 1997).   
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In addition to autosplenectomy, cellular reactions within the body cause 
increased cell adhesion as well as red blood cell dehydration and deoxygenation.  Red 
blood cell dehydration coupled with deoxygenation increases polymerization within 
the erythrocyte thereby increasing sickling.  Increased adhesion and sickling can cause 
tissue ischemia, possibly resulting in a VOC.  This is potentially more serious for 
infection involving the upper respiratory system, which could also cause an ACS 
episode (Booth et al., 2010). 
Treatment 
 The search for treatment for Hb SS met with limited success during the mid- 
twentieth century.  Treatments include parenteral analgesics when needed, blood 
transfusions, and bone marrow transplant (Buchanan et al., 2005;).  As-needed pain 
management is relatively insufficient as an Hb SS treatment because it has no impact 
on future crises.  Also, Hb SS patients who seek treatment at hospitals are often 
viewed as drug-seeking and receive inadequate pain management and care (Yale et 
al., 2000).  Blood transfusions are a viable option as the goal is to introduce red blood 
cells without hemoglobin S (Hb S) in order to reduce the percentage of Hb SS carrying 
erythrocytes.  However, transfusions for Hb SS need to be done frequently and can 
cause an iron overload in patients undergoing them regularly.  This requires additional 
medication or treatment to remove the iron and reduce the risk for iron toxicity 
(Ware et al., 2011). 
Neoplastic Treatment 
 Another option for Hb SS treatment are neoplastic treatments such as 5-
azacytidine and hydroxyurea (HU), which are both ribonucleotide reductase 
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inhibitors.  While the process is not fully understood, it has been shown that 5-
azacytidine and hydroxyurea stimulate the production of Hb F in both children and 
adults by killing cycling cells and allowing gamma globin chains to be expressed 
(Voskaridou et al., 2010).  Texiera et al. (2003) suggest that HU increases Hb F 
production by working “directly on late erythroid progenitors, reprogramming them to 
produce more Hb F.”  Increased levels of Hb F results in a larger percentage of F 
cells, which are simply erythrocytes containing some percentage of Hb F.  Increased 
levels of Hb F and F cells have been shown to reduce the clinical severity of Hb SS 
(Enders et al., 2011; Vicari et al., 2005).  As such, neoplastic treatments are currently 
the best preventative treatment option for Hb SS.  Hydroxyurea has gained notoriety 
as the safer drug, and is the only pharmacologic treatment approved by the Federal 
Drug Administration to treat Hb SS (Green & Barral, 2011), because 5-azacytidine can 
cause bone marrow production to slow down or cease (Charache et al., 1995). 
 Vicari et al. (2005) followed 29 patients on HU treatment for an average of 30 
months, but found that the increase in Hb F was only statistically significant for 
individuals with the CAR haplotype.  Ware et al. (2011) compared the occurrence of 
stroke between Hb SS patients being treated with HU and traditional blood 
transfusions.  Blood transfusion treatment resulted in a marginally greater decrease in 
recurrent strokes, and those not being treated by either method were twice as likely 
to suffer from recurrent strokes (Ware et al., 2011).  In a double-blind trial involving 
299 patients, Maier-Redelsperger et al. (1998) found that HU reduced the occurrence 
of ACS, painful crises, and the need for blood transfusions.  The Multicenter Study of 
Hydroxyurea found that over the course of 2 ½ years the frequency of ACS and painful 
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crises dropped by almost 50% among those treated with HU (Paul et al., 2011).  A 
nine-year study in Greece saw a reduction in hospital admissions, blood transfusions, 
ACS, and painful episodes for people taking HU (Voskaridou et al., 2010).  Steinberg et 
al. (2010) noted a 40% reduction in mortality after just 1 year of HU treatment.  
Overall, it appears that HU treatment effectively reduces symptoms in most Hb SS 
children, but only about half of Hb SS adults.  The results of HU are highly variable 
and warrant further study (Green & Barral, 2011). 
 The sickle cell mutation is a single nucleotide polymorphism capable of causing 
severe and painful symptoms, often resulting in a decreased quality of life and a 
shortened lifespan.  Increased levels of Hb F have been shown to alleviate the clinical 
course of Hb SS in children and adults.  Although three of the five Hb SS haplotypes 
are correlated with differing levels of Hb F, it is the genetic modifiers surrounding the 
sickle mutation that affect Hb F production that are most important in the study of 
differential health outcomes among those with Hb SS and Hb AS.  Unfortunately, the 
production and distribution mechanisms for Hb F are poorly understood.  The 
treatment of sickling episodes usually begins with fluid replacement and 
oxygenization (Kerle et al., 1996).   The lack of a well-defined treatment plan for 
sickling crises can result in poor health outcomes, organ loss, and even death. 
 Sickle cell trait is a genetic mutation that often results in a benign clinical 
course.  However, in some individuals it has the potential to cause significant 
episodes of adverse health and possibly death.  Understanding the genetic differences 
between those experiencing ill health due to Hb AS and those who do not experience 
ill health is the key to determining why these events occur.  Varying levels of Hb F in 
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Hb AS people is one of the genetic differences that may affect health outcomes 
among this group.  Fetal hemoglobin levels are associated with genes carried in the 
Hb AS haplotype, suggesting that determining the haplotype carried may help identify 
those who should be monitored for sudden ill health resembling sickling events.  
Evidence for the association between Hb F, Hb AS, and sickling events is discussed in 
the systematic review presented in the next section, “Do Fetal Hemoglobin Levels 
Mitigate Clinical Outcomes in Hb SS and Hb AS Individuals?”.  Additionally, 
retrospective studies have shown that adverse health events are more common among 
Hb AS individuals who undergo strenuous exercise and exertion, particularly in 
relation to sports and military training.  This evidence is discussed in the systematic 
review of exercise-related deaths in Hb AS beginning on page 37.   
This study has been undertaken to provide evidence for further assessment of 
the association between genes that affect Hb F level and health outcomes in Hb AS 
athletes.  We hypothesize that Hb AS athletes who do not carry genes associated with 
increased and/or persistent Hb F levels are more likely to have suffered ill health 
related to their mutation.  This study is currently in its early stages of recruitment 
and data is not complete.  The following information is descriptive in nature and is 
not appropriate for hypothesis testing. 
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Do Fetal Hemoglobin Levels Mitigate Clinical Outcomes in Hb SS and Hb AS 
Individuals? 
 
Introduction for Fetal Hemoglobin Systematic Review 
   
 Hemoglobin is the substance contained within erythrocytes that carries oxygen 
to tissues through the body.  Normal adult hemoglobin consists of 2 alpha chains (Hb 
A) and 2 beta chains (Hb B); however, hemoglobin is not restricted to these 2 chains 
as different types of hemoglobin are created during different life stages.  The sickle 
cell mutation is a balancing polymorphism that was both advantageous and 
disadvantageous to survival at some point in time, resulting in the selection of the 
sickle mutation by the “watchdog of evolution” and its prevalence among some 
populations (Adekile & Huisman, 1993; Akinsheye et al., 2011; Enders et al., 2011; 
Madrigal, 2011; Miller, 2013; Olaniyi et al., 2010; Sankaran, et al., 2008; Stacy et al. 
1997). 
 During the prenatal and infancy phases of life everyone creates Hb F, which is 
comprised of 2 alpha chains and 2 gamma chains (γ) that are “beta-like” (Sankaran et 
al., 2008).  Fetuses and infants produce Hb F and shortly after birth a “fetal switch” 
takes place, which causes a decrease in the production of the Hb F, replacing them 
with adult Hb B chains.  In non-anemic individuals this eventually results in a low level 
of Hb F.  Normal adults usually have less than 1% Hb F in their total hemoglobin.  
Individuals with Hb SS carry 2 Hb A chains and 2 sickle hemoglobin chains (Hb SS) with 
varying levels of Hb F.  People with Hb SS usually have higher levels of Hb F 
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throughout their lifetime (Adekile & Huisman, 1993; Akinsheye et al., 2011; Enders et 
al., 2011 Olaniyi et al., 2010; Sankaran, et al., 2008; Stacy et al. 1997).  
 Another hemoglobinopathy, known as hereditary persistence of fetal 
hemoglobin (HPFH) is present in some Hb SS and Hb AS individuals, which may be the 
reason they often have higher lifetime Hb F levels.  Hereditary persistence of fetal 
hemoglobin can be deletional or nondeletional.  In deletional HPFH, a section of 
genetic code is missing and results in Hb F production past infancy through the 
overexpression of both the Aϒ and Gϒ genes.  In nondeletional HPFH, usually only one 
of these genes is overexpressed.  There are multiple types of HPFH, but the 2 most 
common in blacks are HPFH-1 and HPFH-2, which are characterized by variable length 
deletions between 13 and 106kb of DNA.  HPFH-1 and HPFH-2 carriers have similar 
mean corpuscular volumes (MCV) and Hb F levels between 20% and 28%.  Deletional 
HPFH usually results in a pancellular Hb F distribution among F cells while 
nondeletional HPFH usually results in a heterozygous distribution pattern (Akinsheye 
et al., 2011; Enders et al., 2011; Forget, 1998; Ngo et al., 2011).  
 Hb F and F cells are 2 of the main modifiers of Hb SS presentation and severity.  
Hb F and F cells, along with other intracellular factors, may be resistant to Hb S 
polymerization depending on the percentage of Hb F present in the F cell.  Therefore, 
erythrocytes containing Hb F are less likely to sickle.  An erythrocyte that cannot 
sickle will either perform as normal or at decreased level, but will not become rigid 
and cause ischemia or infarction (Powars et al., 1989).  Individuals with sickle cell 
anemia who have relatively high levels of Hb F have been shown to have a less severe 
clinical presentation, which can result in reduced morbidity and mortality (Akinsheye 
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et al., 2011; Enders et al., 2011; Ma et al., 2007; Maier-Redelsperger et al., 1998; 
Marcus et al., 1997; Murray et al., 1987; Ngo et al., 2011; Olaniyi et al., 2010; Powars 
& Hiti, 1993; Vicari et al., 2005; Ware et al., 2011).  Multiple studies have found that 
any increase in Hb F is not necessarily sufficient to reduce clinical severity of Hb SS.  
It has been shown that in order to reduce morbidity and mortality in Hb SS the 
percentage of Hb F must be at least 15% of total hemoglobin, though the best results 
occur when more than 20% of the total hemoglobin is Hb F (Marcus et al., 1997; 
Powars et al., 1984).  After a 17 ½ year study on the effectiveness of using 
hydroxyurea to increase Hb F levels, Steinberg et al. (2010) concluded that, 
“sufficiently high concentrations of Hb F evenly distributed among sickle erythrocytes 
can totally abrogate the disease pathophysiology.” 
 Levels of Hb F persistence have been linked to the different Hb SS haplotypes.  
Specifically, the Senegal and Arab/Indian haplotypes have been found to have higher 
levels of Hb F and a generally mild clinical course of Hb SS.  People who are 
homozygous for the Senegal haplotype are often found to have approximately 20% Hb 
F.  The Benin haplotype has been shown to have intermediate levels of Hb F and a 
moderate clinical course.  The CAR haplotype has the worst clinical course and the 
lowest amount of Hb F at approximately 5%.  The linkage between Hb F, Hb SS 
haplotype, and clinical course is complicated in countries where people with African 
heritage are primarily found as result of the historical slave trade.  As a result, these 
haplotypes were more common in certain countries and areas before global travel 
became more commonplace.  Today, it is unknown how haplotypes are distributed 
throughout the U.S.; this is also due largely to the fact that Hb AS and Hb SS 
	  	   14	  
haplotypes are rarely determined through genetic testing.  Thus, there is no data 
regarding haplotype frequency and distribution through the United States.  These Hb 
SS individuals are often heterozygous for 2 sickle haplotypes due to the admixture of 
genes found during and since slavery.  Generally, individuals with at least 1 Senegal 
haplotype sickle cell gene can expect to have a moderate to mild clinic course with 
an onset of symptoms in adulthood.  Individuals with at least 1 CAR haplotype sickle 
cell gene can expect a severe to moderate clinical course, with an increased level of 
soft tissue organ failure, osteonecrosis, and a shortened lifespan (Akinsheye et al., 
2011; Powars et al., 1994; Powars & Hiti, 1993). 
 Within the last three decades it has become clear that Hb F levels can 
positively influence clinical outcomes in those with Hb SS.  Unfortunately, not many 
studies have been conducted that assess the clinical differences between sickle cell 
haplotypes, other sickle hemoglobinopathies, and variation in Hb F levels.  Recent 
studies have indicated that genetic modifiers surrounding the sickle cell mutation 
code for higher levels of Hb F in some sickle cell haplotypes.  These studies, however, 
also include information pertaining to co-morbidity with other hemoglobinopathies, 
which can influence clinical outcomes of those with Hb SS.  This systematic review 
was conducted in order to determine if Hb F levels above 20% are protective against 
sickling events in Hb SS individuals.  This review fills a unique niche, as no prior 
systematic reviews on this topic exist.  
Methods for Fetal Hemoglobin Systematic Review 
 Identification of literature for this review did not follow typical systematic 
review procedures.  The author was not aware that she would need to write a 
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systematic review until she had already been collecting literature for a year, and thus 
she did not document the entire process.  Early articles were either found through the 
Web of Knowledge Database or were provided to the author by co-investigators.  The 
author has found the Web of Knowledge database to be the most efficient way to 
identify articles across disciplines.  
 The author had already obtained articles that were included in this review 
(found between September 2011-February 2013) before record keeping was initiated, 
which began in March 2013. Articles found during and after March 2013, were 
discovered through the Web of Knowledge Database using search terms including the 
phrases, “sickl*”, “cell”, “trait”, “fetal”, “hemoglobin”, “foetal”, “hemoglobin*”, 
and “haemoglobin*”.  The author has found the Web of Knowledge database to be the 
most efficient way to identify articles across disciplines.  The author has also found 
that Web of Knowledge is the most likely to provide full versions of the required 
article, and is the best source to find specific articles by title and author.  Articles 
were eligible for inclusion if they were published in English during any time period, 
published within all health and science disciplines, and of any study types or design 
including, but not limited to, prospective and retrospective cohorts, case-control, 
randomized clinical trials, case series, case reports, and cross sectional.  
Commentaries, brief reports, and reviews that were not systematic reviews, were not 
eligible for inclusion as they would not provide data for the systematic review. Only 
studies on humans were eligible for inclusion in this review, as the sickle cell 
mutation does not occur within other species.   
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 With all search results combined, 3,971 articles were originally identified.  
Many of these articles were not related to the topic of interest, which was identified 
by reading the abstract.  Additionally, many articles were duplicates, which were 
identified while saving the articles in PDF format.  Ultimately, 78 articles were 
reviewed for inclusion in the study.  Four papers met all inclusion criteria.  An 
additional article was identified through the citations of these articles.  A total of 8 
articles were included in this review.  The specific search terms used can be found in 
Table 1.  All tables and figures for this section can be found at the end of this 
chapter.  A flow chart identifying the steps used to identify later articles is show in 
Figure 1.  Studies were included in this review if they confirmed diagnosis of Hb AS or 
Hb SS and measured levels of Hb F regardless of study design.   Studies were excluded 
from this review if they did not measure levels of Hb F or if they focused on the 
genetic modifiers influencing Hb F instead of clinical outcomes.  Articles written at 
any time period were eligible for inclusion so long as they met the inclusion criteria.  
In total, 8 papers met the inclusion criteria and were selected for this review.   
 A scoring system to assess the quality of the papers was created based on the 
scoring system found in Dino et al.’s 2009 study.  Papers were scored on a 22-point 
scale, as the quality of the papers over time made it difficult to create a more 
specific scoring system.  The scores were used to assess the reliability and validity of 
the study, but did not affect their inclusion in this review. The scoring chart created 
for this review is available in Figure 2.  A clear statement of the hypothesis and the 
use of a sample size under 50 were each worth 1 point.  However, reporting a sample 
size over 50 was worth 2 points as was the representativeness of the target 
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population.  A description of the inclusion and exclusion criteria for participants was 
worth 1 point. The inclusion or discussion of important variables, some of which were 
potential confounders, was worth up to 6 points.  The following variables were worth 
1 point each: Hb F levels, age, gender, α-thalassemia status, GP6D deficiency status, 
and hemoglobin C status.  The description of statistical analyses used and the 
inclusion of a power calculation was worth 1 point.  If statistical outcomes were 
reported the paper received 1 point, but 2 points were awarded for thorough 
statistical outcomes, such as the inclusion of a p-value or confidence interval. Papers 
received 1 point if they contained a clear statement regarding whether or not the 
final data supported the hypothesis.   Scores for each paper can be found in Table 2. 
Results for Fetal Hemoglobin Systematic Review 
  
 The majority of the studies (n = 7) did not differentiate between the types of 
Hb FP, with only 1 study creating separate groups for both HPFH-1 and HPFH-2.  
Within the 8 studies reviewed there was 1 randomized controlled trial, 1 case-control, 
2 prospective cohorts, and 4 cross sectional designs.  Four of the studies were 
conducted within the United States, 1 in France, 1 in Jamaica, 1 in Kuwait, and 1 was 
conducted with data from multiple international centers.  All studies used data or 
participants from clinical settings including hospitals, SCD centers, hematology 
clinics, or longitudinal hematology studies.  Four studies examined only pediatric data 
while the remaining 5 included participants of all ages.  Only 2 of the 8 studies 
reported both p-values and confidence intervals for their findings, with 6 studies 
reporting p-values, and 1 study reporting only group means and standard deviations.  
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A summary table displaying the p-values, location, study designs, and confidence 
intervals where appropriate, can be found in Table 3. 
Randomized Control Trial 
 In 2013, Sheehan et al. used data from the BABY HUG study, which was a 
placebo-controlled, double-blinded phase III randomized control trial sponsored by 
the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of 
Child Health and Human Development (NICHHD).  This study looked at the effects of 
HU use in 190 children under the age of 4 years in order to look at the differential 
clinical outcomes associated with HPFH genetic modifiers and increased Hb F through 
the use of HU in relation to adverse clinical events in young children.  To do this the 
investigators utilized 13 centers around the United States (U.S.) to record data on 
sickle cell haplotypes, Hb F modifiers, other hemoglobin disorders, and Hb F levels, 
among other variables.  Patients were enrolled between the ages of 9 months and 18 
months and followed for a period of 2 years.  The study measured Hb F levels upon 
entry and exit to the study in both placebo and intervention groups.  Using 
information that correlated severity of clinical outcome to sickle haplotype, the 
authors sorted the participants into favorable, intermediate, and unfavorable 
subgroups.  However, this only took three of the five sickle haplotypes into 
consideration as data on clinical severity and haplotype is scarce (Sheehan et al., 
2013). 
 Sheehan et al. (2013) also divided placebo and intervention groups by alpha-
thalassemia status as infants with this disorder presented with substantial clinical 
differences when compared to those without the disorder.  Upon entry to the study, 
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the Hb F level for all participants was approximately 26%, but was not statistically 
significant between alpha-thalassemia groups (p-value = 0.56).  Upon exit, neither the 
placebo group nor the intervention group showed statistically significant differences 
in Hb F levels by alpha-thalassemia status.  The authors found that among the placebo 
group the genetic modifiers examined were associated with a higher baseline Hb F 
level, but this was not seen upon exit from the study.  Among the intervention group 
Hb F levels were higher regardless of the presence or absence of these genetic 
modifiers.  Ultimately, Sheehan et al. (2013) state that infants within the favorable 
sickle haplotype group had higher baseline levels of Hb F, but that this did not persist 
throughout the study.  Interestingly, this group also had higher rates of pain events 
than the beta-globin haplotype.  They conclude that sickle haplotype does not 
influence response to HU and determining the haplotype is not necessary, as it does 
not help predict clinical outcomes for HB SS individuals (Sheehan et al., 2013).    
Prospective Cohort 
 Powars et al. (1984) conducted a prospective cohort study to gather 
information on Hb F levels in Hb SS individuals with the belief that there may be a 
threshold level of Hb F that was indicative of increased risk, though they stated that 
their primary purpose was not to test a specific hypothesis.  Instead, they conducted 
an observational study designed to collect data that could be used to help generate 
hypotheses in the future. The study recruited 272 participants of both sexes in the 
original cohort ranging in age from birth to 56 years.  Data collection began in 1974, 
and participants were followed for an average of 11 years.   Two hundred and sixteen 
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participants remained in the study after 11 years.  It is unclear where and how 
participants were recruited (Powars et al., 1984).   
 The authors looked at the recurrent events of sickle cell crisis, chest syndrome, 
meningitis/septicemia, and hospitalizations as well as the fatal events of 
cerebrovascular accidents (CVA), and aseptic necrosis in relation to a range of Hb F 
levels.  They found a linear incidence pattern for crisis, hospitalization, and chest 
syndrome among age-adjusted results for individuals who had 15% or greater Hb F 
levels.  There was no pattern apparent among unadjusted data.  Interestingly, 
participants who consistently had Hb F levels around 20% had lower incidence rates 
than those who consistently had levels with the 15 – 19% range.  
Meningistis/septicemia did not follow this pattern and the authors felt that it was due 
to the high occurrence rates among young children who have variable levels of Hb F.  
They state that it may also be due to the limited number of cases available for study.  
There were also a small number of aseptic necrosis and CVA cases available for 
analysis.  Aseptic necrosis appeared to have an increased incidence among those with 
less than 10% Hb F while CVA had an increased rate among those with 15-19% Hb F.  
The authors chose 10% Hb F to be the threshold point for these events.  Powars et al. 
(1984) found that among recurrent events, the risk ratio decreased with Hb F levels 
above 20%, and even more significantly among those with Hb F levels above 25%.  
Termination events had a decreased risk ratio beginning at 10%, but results showed 
that risk was not substantially less and was reduced only at intermediate levels.  They 
conclude that there is no linear pattern associated with decreased risk for Hb F 
	  	   21	  
levels, but that the data supports the idea that a threshold level exists whereby 
incidence of recurrent and fatal events is decreased (Powars et al., 1984).  
 Using data gathered from the multi-center French Study Group on Sickle Cell 
Disease, Maier-Redelsperger et al. (1998) investigated the association between the 
use of HU, myelotoxic events, and Hb F levels in a pediatric cohort.  Males and 
females between the ages of 4 and 19 years were recruited for this study, resulting in 
a total sample size of 29.  Participants must have had at least three sickle cell related 
pain events that required hospitalization within the last year in order to be eligible 
for the study.  Participants were followed for an average of 22 months.  Four 
participants were lost to follow-up due to a failure to respond to treatment (2), 
relocation (1), and development of systemic lupus (1).  With the use of HU, the 
investigators found increased Hb F levels in all participants not lost to follow up.  The 
authors also determine sickle haplotype for 24 participants from the original cohort 
and examined the association between haplotype and Hb F level. Nine of the patients 
were homozygous for the Benin haplotype, 8 were homozygous for the CAR haplotype, 
three were homozygous for the Senegal haplotype, three were heterozygous for the 
CAR and Benin haplotypes, and 1 was atypical (Maier-Redelsperger et al., 1998).   
 The investigators found that after three years with HU treatment Hb F levels 
increased between 1.5-fold and 16-fold among participants.  They found variation 
among initial Hb F levels between haplotypes, but the difference between those 
levels and maximal levels after HU usage were not statistically significant. 
Additionally, there were no adverse events associated with HU use in this study.  The 
authors state that the results suggest the use of HU may be more beneficial in 
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subadults than adults, but requires further study to examine its pleiotropic effects 
(Maier-Redelsperger et al., 1998).  
Cross Sectional 
 Bhatnagar et al. (2013) conducted a cross sectional study using data from the 
Silent Infarct Transfusion (SIT) trial, conducted by the National Institute of 
Neurological Disorders and Stroke, and the Cooperative Study of Sickle Cell Disease 
(CSSCD) that is funded by the NHLBI.  They collected data on VOC pain episodes and 
Hb F levels from one 2,220 participants:  456 from the SIT and trial and 764 from the 
CSSCD.  Participants were both male and female and between the ages of 2 and 15 
years.  The authors looked at hematocrit levels, age, Hb F levels, and sex in relation 
to incidence of VOC pain crises.  In the SIT trial hematocrit levels and age were 
strongly associated with increased pain episodes, with p-values of <0.0001 each.  Sex 
and Hb F levels were not significantly associated with pain episodes, having p-values 
of 0.54 and 0.07 respectively.  Similar results were found in the CSSCD study, with age 
and hematocrit levels having statistically significant p-values of 0.0016 and 0.019 
respectively.  Hb F level had a p-value of 0.15 while sex had a p-value of 0.67.  
Bhatnagar et al. (2013) then conducted a meta-analysis of the results from these 2 
studies.  In the meta-analysis age and hematocrit levels remained statistically 
significant and Hb F was also found to be associated with incidence of VOC pain 
episodes.   Hematocrit and age both had p-values of <0.0001 and Hb F had a p-value 
of 0.02.  Sex was not found to be strongly associated with pain episodes with a p-
value of 0.46.  The authors note that single-point measurements of Hb F may be a 
limitation of the study, but that Hb F levels in children of the ages included remain 
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fairly constant and thus were believed to be accurate representations.  Additionally, 
pain episodes were recorded retrospectively in the SIT trial and therefore may not 
include data from all medical centers.  They conclude that Hb F levels are associated 
with incidence of pain episodes and suggest that further research into this association 
is warranted (Bhatnagar et al., 2013). 
 A unique study cross-sectional study was conducted in Kuwait by Adekile et al. 
(2007) investigated Hb F levels among Kuwaiti people.  Participants were recruited 
from hematology clinics at the Amiri and Mubarak hospitals, were of both genders, 
and ranged in age from 3 months to 60 years.  A total of 149 participants were 
recruited for the study.  Sickle cell haplotype was determined and only those carrying 
the Saudi Arabia/Indian (SAI) haplotype, either homozygously or heterzygously, were 
included.  Of the 149 participants, only 4 were not homozygous for the SAI haplotype; 
these 4 were heterozygous for the SAI and Benin haplotypes.   
 The authors divided participants into age ranges of <5 years, >5 – 10 years, > 10 
to 15 years, and > 15 years and found that mean Hb F levels were significantly 
different throughout these groupings with a p-value of <0.0001.  They found that most 
patients in this population have Hb F levels between 20% and 30%.  Fetal hemoglobin 
levels decreased from 1 year of age to 5 years of age, but then tended to remain 
fairly steady in this population.   The authors believe these high Hb F levels are the 
reasons Kuwaiti people with Hb SS tend to have more mild clinical courses.  This is 
especially evident in Kuwait children, who do not usually present with Hb SS 
symptoms until after 5 years of age when their Hb F levels have dropped below 30% 
(Adekile et al., 2007). 
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 Marcus et al. (1997) used a cross sectional design and recruited patients with 
SCD from the Duke Pediatric Hematology Clinic that is within the Duke-UNC 
Comprehensive Sickle Cell Center in order to quantitate F-cells, which are cells 
containing any percentage of Hb F, among those with SCD.   Two hundred and forty-
two patients of both sexes between the ages of 2 and 19 ½ were recruited.  Eight of 
the participants had Hb S/HPFH, 30 had Hb S and a beta-thalassemia, 74 had Hb SC, 
and 130 had Hb SS.  Individuals with Hb SS were reported to have Hb F levels 
10.4+6.3% while those with Hb S/HPFH had Hb F levels of 31.7+3.0, which was 
statistically significant with a p-value of <0.001.  A significant correlation, with a p-
value of <0.001, was also found between % F cell and hemoglobin concentration 
among Hb SS children.  Marcus et al. (1997) note that the percentage of intracellular 
Hb F in F cells varies and is not related to the Hb F levels through the body.  If the 
two were linked, it would be easier to predict Hb F or F cell levels from the 
measurement of the other.   This is important because an understanding of the 
relationship between these two variables could benefit the treatment of SCD.  
Ultimately, the authors conclude that %Hb F and %F cells needs to be measured in all 
Hb SS individuals receiving clinical treatments such as hydroxyurea in order to more 
fully understand its interaction with other clinical parameters and thus the help 
determine more beneficial treatments for patients (Marcus et al., 1997).   
 A study conducted in Jamaica in the mid-1980’s by Murray et al. (1987) 
compared the hematological characteristics of individuals with Hb SS, Hb S-HPFH, and 
Hb S-beta-thalassemia.  The investigators recruited participants from those attending 
sickle cell clinics at the University Hospital of the West Indies in Kingston, Jamaica.  
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Participants were between the ages of 6 and 33 years and both male and female.  
There were a total of 27 participants included in the study.  Identification of potential 
participants was based on diagnosis of the hemoglobinopathies in a parent or sibling.  
It is unclear whether all hemoglobinopathies were clinically confirmed in participants, 
but HPFH was confirmed through the testing for cord- blood in 6 of the participants, 
and 7 were confirmed through family study.  However, Hb F levels were tested and 
only those with 20% or more Hb F were eligible to participate in the study.  Beta-
thalassemia was clearly differentiated from the other hemoglobinopathies by levels of 
HbA2.  Erythrocyte count provided a clear distinction between Hb S-HPFH and Hb SS, 
followed by Hb F levels though the authors state that the addition of Hb F levels to 
erythrocyte count was not substantial.  In 3 of the 4 patients with Hb S-beta-
thalassemia blood cell films showed irreversibly sickled cells.  Irreversibly sickled cells 
were also present in 4 out of ten participants with Hb SS, but were not present in any 
of the 13 Hb S-HPFH participants.  The authors conclude that it should be possible to 
differentiate between Hb S-HPFH and Hb SS with high levels of Hb F based on 
measurement of Hb F: Hb F ranges were only high enough in 2 of the Hb SS 
participants to overlap with Hb S-HPFH Hb F levels.  They state that it should be 
possible to differentiate between Hb SS and Hb S-HPFH by the hematological features 
of red blood cell count and Hb F level, followed by reticulocyte count, total 
hemoglobin, and total bilirubin in most cases.  Differentiation between those with Hb 
S beta-thalassemia should be possible through the measurement of HbA2 levels.  
Limitations of this study include a small sample size.  Clinical diagnoses were limited 
by the techniques available at the time of the study (Murray et al., 1987). 
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Case-Control 
 In 2011, Ngo et al. gathered data on Hb F levels among those with Hb SS.  
Participants included both sexes and ranged in age from newborn to 62.2.  Using the 
Haemoglobin Diagnostic Reference Laboratory at Boston Medical Center the authors 
identified 28 participants with both types 1 and 2 HPFH.  They also conducted a 
retrospective chart review to obtain data on longitudinal Hb F levels.  They compared 
the results of their study to an external reference group using data from 4,085 in the 
CSSCD and also identified participants who carried the XmnI polymorphism that is 
associated with increased Hb F levels.  There were 20 participants with HPFH-2 and 7 
participants with HPFH-1.  Within their group they found that increased levels of Hb F 
were associated with decreased sickle cell events.  Additionally, the average Hb F 
level did not differ between HPFH types 1 and 2, having a p-value of 0.26.  Using data 
from the CSSCD as a comparison for their study the investigators found that Hb F level 
for all ages and also for those over five years, MCV, haemoglobin levels, and 
reticulocyte level were all significantly increased in those with HPFH:  p-values for 
each variable were <0.01.  Ngo et al. (2011) also compared those with the XmnI 
polymorphism group to the CSSCD group and found that all variables except 
reticulocyte level were significantly increased, with all p-values again at <0.01.  
Reticulocyte level had a p-value of 0.09 in this group.  The authors state that Hb F 
levels decreased among those with HPFH and the XmnI after infancy, but that the 
decline is not as steep as that seen among groups without these polymorphisms.  They 
suggest that the regulatory mechanism for Hb F may differ among these groups.   Ngo 
et al. conclude that Hb SS individuals with Hb F levels at or above 30% have fewer or 
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less severe sickling events and that a more thorough understanding of Hb F 
distribution and regulation may aid in the treatment of Hb SS individuals (Ngo et al., 
2011). 
Discussion for Fetal Hemoglobin Systematic Review 
Hb F is a quantitative trait with great variation in the amount of Hb F produced 
in each haplotype.   Among the numerous factors have been found to influence the 
phenotypic expressions of Hb F are gender, age, and genes located on different 
chromosomes.  Chang et al. (1995) state, “within populations of SS patients that are 
relatively homogeneous for their β-globin haplotypes, other variables must play a 
more dominant role in determining Hb F levels. Analyses of pedigrees with variable Hb 
F levels have indicated that Hb F is also influenced by genetic factors unlinked to the 
β-globin region.”  They identified three DNA polymorphisms that modify Hb F 
productions: BCL11A, Hb S1L-MYB, and the beta globin locus.  They found that Hb F 
levels were most strongly influenced by the F cell production locus located on the X 
chromosome, which indicates that females with Hb SS may have more mild clinical 
complications (Chang et al., 1995).  Galarneau et al. (2010) studied the same three 
polymorphisms using a genome wide association study.  They were able to link seven 
single nucleotide polymorphisms (SNPs) that independently affect Hb F production, 
but found that only the original three were statistically significant.  They also found 
that the three previously identified SNPs were responsible for approximately 23 % to 
30% of the variation in Hb F in Hb SS individuals (Galarneau et al., 2010; Higgs & 
Wood, 2008).  In 2005, Sankaran et al. (2008) found that the BCL11A single nucleotide 
polymorphism actually works through epistasis by suppressing the production of 
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gamma chains for Hb F and may be responsible for the “fetal switch” that occurs 
shortly after birth.  The phenotypic expression of Hb F by Hb SS individuals is variable 
and, according to Galarneau et al.’s (2010) work, illustrative of the central limit 
theorem. 
 Evidence from these studies indicate that levels of Hb F at 20% or greater 
results in better clinical outcomes for Hb SS individuals.  Though many 
hemorheological features influence sickling in erythrocytes, the percentage of Hb F in 
each F cell is what controls whether or not the cell will sickle during vaso-occlusive 
events.  It is not understood, however, what mechanism(s) control the intracellular 
distribution of Hb F within erythrocytes:  levels may be distributed equally throughout 
cells or may vary between cells.  Higher %Hb F levels thus increase the availability of 
Hb F for distribution and increase the likelihood of more mild clinical courses.   
Strengths of this Review 
 Strengths of this study include its inclusion of studies conducted in multiple 
countries and across the last three decades.  The inclusion of multiple study designs 
also benefits this review by helping to reveal and compensate for design limitations in 
each type.   
Limitations of this Review 
 This study is limited in a number of ways.  To begin, it may not be an accurate 
representation of the available literature since articles were only eligible for inclusion 
if they had been published in English.  Although the search terms used were broad, 
they may not have revealed all articles eligible for inclusion in this study.  
Additionally, only the author reviewed articles for inclusion and scored them for 
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methodological quality.  The use of multiple scorers may have resulted in the 
inclusion of different articles or the exclusion of ones reviewed.  Reviewers with a 
high inter-rater reliability would have helped this review achieve higher validity and 
reproducibility.  Another limitation is present in the populations chosen for this 
review, which may not accurately represent all individuals with SCT as many of 
samples were comprised of non-adults.     
Limitations of Studies Included in this Review 
 Limitations of this study stem largely from the individual limitations posed by 
each study included in the review.  The small sample of studies included is also 
potentially problematic as it may not fully represent all studies with data pertaining 
to Hb F levels in Hb SS individuals.  Indeed, a number of studies were not included as 
their methods were unclear and the data presented was unintelligible.  
Conclusion of Fetal Hemoglobin Systematic Review 
 Fetal hemoglobin persistence, its distribution, and mechanism regulating 
production levels warrant further research.  This understanding would make the use 
of pharmaceuticals more beneficial by allowing medical care providers to understand 
the processes and likely outcomes before administering potentially toxic drugs to 
those already suffering ill health.  It is clear that further research on the effects of Hb 
F on erythrocyte sickling is needed.  This is especially important as SCD and Hb AS 
children age and their natural Hb F levels drop, decreasing their protection from 
sickling crises.  
 Based on the evidence in this review, increased fetal hemoglobin levels can 
positively influence the occurrence and severity of pain episodes in those with Hb SS 
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and Hb AS.  However, the mechanisms controlling HPFH are poorly understood.  Genes 
coding for Hb F persistence are beginning to be identified, but it is still unclear how 
these genes affect the levels of Hb F produced and why they vary through the life 
course.  In addition, the distribution of Hb F through erythrocytes is often not 
uniform; mechanisms controlling the distribution process have not been identified.  
Given the ambiguity surrounding the protective measures provided by Hb F it is not 
possible to say exactly what levels are protective.  Evidence provided herein suggests 
that high Hb F levels can be found among some haplotypes and that levels above 20-
30% help mitigate the effects of sickling in Hb SS and Hb AS individuals.  
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Hb F Search Terms
sickl* cell trait fetal foetal haem* hem*
sickl* and cell and trait and fetal and hem*
sickl* and cell and trait and fetal and haem*
sickl* and cell and trait and foetal
sickl* and cell and fetal and hem*
sickl* and cell and fetal and haem*
Tables and Figures  
Table 1. Search Terms Used to Identify Articles Potentially Eligible for Inclusion in     
     this Review 
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          







 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow chart detailing articles identified for possible inclusion in this review  
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Hypotheses (maximum possible = 1) 
• The hypothesis/research question of the study not clearly described = 0 
• The hypothesis/research question of the study clearly described = 1 
Study Type (maximum possible = 5) 
• Systematic Review = 5 
• Randomized Control Trial = 4 
• Cohort Study = 3 
• Case-Control = 2 
• Case Series OR cross sectional = 1 
Sampling (maximum possible = 5) 
• Sample Source and Size 
• Routine data = 0 
• Sample size less than 50 = 1 
• Sample size more than 50 = 2 
• Sampling Representation (2) 
• Not representative of target population = 0 
• Representative of target population = 2 
• Selection Criteria 
• Selection of cases/controls/population not well described = 0 
• Selection of cases/controls/population well described = 1 
Methodology (maximum possible = 6) 
• Inclusion of other variables: 
• Age = 1 
• Hb F = 1 
• Alpha-Thalassemia = 1 
• Gender = 1 
• Hb SC = 1 
• Hb S = 1 
Statistical Analyses and Results (maximum possible = 5) 
• Statistical Analysis (2) 
• Statistical methods not described = 0 
• Statistical methods clearly described = 1 
• Statistical outcomes (2) 
• Statistical outcome not clearly reported = 0 
• Some statistical outcomes clearly reported (e.g. CI’s but not P-values) = 1 
• Statistical outcomes clearly reported (e.g. CI’s and P-values) = 2 
• Results (1) 
• Research questions/hypotheses not clearly answered/tested = 0 
• Research questions/hypotheses clearly answered/tested = 1 
 
Maximum Score = 22 
 
Figure 2. Methodological quality scoring sheet used to assess the studies included in 
this review 
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Is Physical Exertion and/or Exercise a Risk Factor for Sudden Death Among Hb AS  
 
Carriers? 
 
Introduction for Exercise Deaths Systematic Review 
  
 Recently, it has become clear that some Hb SS patients have more benign 
clinical profiles than others.  If a sickling crisis is not stopped by prompt medical 
attention it may result in patient death. Fortunately, the genetic reason for such 
clinical differences has been well determined: although the mutation that alters the 
“normal” hemoglobin gene is the same in all patients, genetic modifiers surrounding 
the sickle gene influence the clinical course.  Specifically, there are SNPS in several 
chromosomal areas that affect the production of fetal hemoglobin (Hb F).  If higher 
than normal Hb F levels are produced, the clinical course is less severe; if Hb F is 
produced at average levels, the clinical course is more severe (Adekile et al., 2007;  
Akinsheye et al., 2011; Bailey et al., 1991; Bhatnagar, 2013; Charache & Conley; 
1969; Ender et al., 2011; Forget, 1998; Franco et al., 2006; Jacob & Raper, 1958; 
Marcus et al., 1997; Ngo et al., 2011; Powars et al., 1984; Powars et al., 1989; 
Sheehan et al., 2013; Steinberg & Sebastiani, 2012; Whyte et al., 2013).   
For several years, it was thought that the genetic material surrounding the 
beta gene, which is usually referred to as the beta-globin sickle haplotype or Hb S 
haplotype, was responsible for the different clinical manifestations of sickle cell 
anemia.  However, it is clear now that Hb SS individuals who have a milder disease 
course have elevated levels of Hb F because their γ-globin gene remains active, while 
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it is inactivated soon after birth in most “normal” people.  The higher levels of Hb F 
make up for the defective Hb S, leading to a milder clinical course (Bhatnagar et al. 
2011; Farrell et al. 2011; Lettre et al. 2008). In addition, other hemoglobinopathies 
such as the thalassemias (which are themselves highly variable) modulate the clinical 
manifestation of sickle cell disease (Badens et al. 2011).  In sum, the genetic basis to 
the differential clinical manifestation of sickle cell disease is best explained by the 
patient’s SNPs at loci that affect fetal beta globin expression.   
  Clinical outcomes among those with SCD and Hb AS vary in severity.  This is 
especially evident among Hb AS athletes, who sometimes suffer from ES or heat 
illness.  Exertional sickling has often been confused with other causes of collapse 
among those who are exercising.  Although symptoms differ, it is often mistaken for 
severe forms of heat illness.  Symptoms of exertional sickling often include cramps 
that spread throughout the body, leg and/or low back pain, weakness, trouble 
catching one’s breath, tightness in the chest, rapid breathing, or just not feeling 
“right” (Eichner, 2010).  In many Hb AS individuals ES crises progress into muscle 
sickling, muscle infarction, and can result in rhabdomyolysis, which is the breakdown 
of muscle fibers (Kerle et al., 1996; Koppes, 1977; Rhabdomyolysis, 2013).  When 
rhabdomyolysis occurs, myoglobin, which is a protein contained within the muscle, is 
released into the bloodstream.  Myoglobin damages kidney cells and can cause kidney 
failure.  If not treated quickly, rhabdomyolysis can cause severe clinical outcomes and 
possibly death.  Among Hb AS athletes, death is often attributed, at least in part, to 
rhabdomyolysis and may contribute to incorrectly identified causes of death and 
therefore inaccurate Hb AS death rates.  
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 Considering that the age category containing college students has a very low 
mortality rate, and that these are elite athletes in excellent physical health, these 
mortality numbers are rather high and should be cause for concern.  As discussed in 
the introduction, there have been approximately 18 deaths due to Hb AS among 
athletes over the last few decades.  Indeed, it is only recently that Hb AS has been 
acknowledged as a cause of death in the general population.  Our work with all U.S. 
States which record this as cause of death indicates that the frequency of sickle-cell 
deaths is not as low as it was once assumed.  We summarize these data in Table 4.  
All tables and figures for this section can be found at the end of this chapter. It is 
clear that states with high concentrations of African-derived populations and those 
with high altitudes have higher frequencies of Hb AS-related deaths.  A map of deaths 
Hb AS deaths reported in this states can be found in Figure 3. 
Sickle cell trait has also been listed as a cause of death in military personnel 
during strenuous physical training exercises.  It is possible that outside conditions, 
such as higher temperatures, humidity, and elevation can increase the risk of having a 
sickling crisis.  In addition to these conditions, intense physical training and conditions 
may exacerbate the sickling crisis and lead to severe or fatal health outcomes.  This 
systematic review includes all available studies regarding death from or relating to Hb 
AS in athletes and military personnel in the U.S. in order to determine whether or not 
there is an increased risk of death in Hb AS individuals who engage in strenuous 
physical activities.  This review fills a unique niche, as no prior systematic reviews on 
this topic exist. 
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Methods for Exercise Deaths Systematic Review 
The author had already obtained three articles that were included in this 
review (found between September 2011-February 2013) before record keeping was 
initiated, which began in March 2013.  Articles found during and after March 2013, 
were discovered through the Web of Knowledge Database using search terms including 
the phrases, “sickle”, “cell”, “trait”, “athlete*”, “exercis*”, and “physical”.  Articles 
were eligible for inclusion if they used military or athlete populations, recorded Hb AS 
as a cause of death or related cause of death, and reported the participants’ physical 
activity level preceding the crisis episode.  Eligible articles were published in English 
during any time period, published within all health and science disciplines, and of any 
study type or design including, but not limited to, prospective and retrospective 
cohorts, case-control, randomized clinical trials, case series, case reports, and cross 
sectional.  Commentaries, brief reports, and reviews that were not systematic 
reviews, were not eligible for inclusion as they would not provide data for the 
systematic review. Only studies on humans were eligible for inclusion in this review, 
as the sickle cell mutation does not occur within other species.  
With all search results combined, 3,087 articles were originally identified.   
Many of the articles identified were not related to the topic of interest, which was 
identified by reading the abstract.  Additionally, many articles were duplicates, which 
were identified while saving the articles in PDF format.  From this, 55 articles 
matching the research aims of the author were reviewed for inclusion in this review.  
After reviewing these 55 papers, only 4 met all inclusion criteria, which was the 
included the reporting of data pertaining to episodes of pain or sudden death 
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associated with Hb AS status and the inclusion of data regarding whether or not the 
participant was engaged in physical exercise prior to the attack.  Five additional 
articles were identified through the citations of articles already selected for this 
thesis.  Two of these articles were requested through USF’s Interlibrary Loan (ILL) 
program, but the ILL staff was unable to obtain copies of the articles.  An additional 
article was identified through an article in Scientific American in which this study was 
mentioned.  Studies were excluded from this review if they were case studies of a 
single patient, only discussed the topic generally without including data, or did not 
report outcomes of sickling crises or death.  In sum, a total of 8 papers were included 
in this systematic review.  The specific search terms used can be seen in Table 5.  A 
flow chart identifying the steps used to identify later articles is shown in Figure 4.   
A scoring system to assess quality of the papers was created based on the 
scoring system found in Dino et al.’s 2009 study.  Papers were scored on a 17-point 
scale, as the quality of the papers over time made it difficult to create a more 
specific scoring system.  The scores were used to assess the reliability and validity of 
the study, but did not affect their inclusion in this review.  The scoring chart created 
for this review is available in Figure 5.  A clear statement of the hypothesis and 
reporting a sample size under 50 was both worth 1 point.  However, a paper was given 
2 points if the sample size was over 50 participants.  Representativeness of the target 
population was also worth 2 points.  A description of the inclusion and exclusion 
criteria for participants was worth 1 point. The inclusion or discussion of important 
variables, some of which were potential confounders, was worth up to 6 points.  The 
following variables were worth 1 point each: Hb F levels, age, gender, α-thalassemia 
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status, GP6D deficiency status, and hemoglobin C status.  The description of 
statistical analyses used to analyze data and the inclusion of a power calculation was 
each worth 1 point.  If statistical outcomes were vaguely reported the paper received 
1 point, but 2 points were awarded for thorough statistical outcomes, such as the 
inclusion of a p-value or confidence interval.  Papers received 1 point if they 
contained a clear statement regarding whether or not the final data supported the 
hypothesis.  Scores for each paper can be found in Table 6. 
Results for Exercise Deaths Systematic Review 
 
 All 8 papers reported studies that were conducted within the United States.  
Seven papers utilized retrospective cohort designs in order to gather their data and 
the remaining paper was a small retrospective case series.  Five of the studies looked 
at athlete populations while the other three looked at members of the armed forces.  
Five of the studies gathered information on gender, though all studies included 
predominantly male data.  Sickling crises and death related to Hb AS in athletes has 
only been recorded in 2 female athletes as far as the author has been able find.  Six 
studies recorded data on race, but only differentiate between Caucasian and African 
American (AA) identification, which does not take the Hb AS rate 0.5% among those of 
Hispanic/Latino descent into account (Tarini et al., 2012).  Measures of association 
varied between the studies, with statistical outcomes vaguely reported on the whole.  
A summary table displaying measures of association, confidence intervals, and p-
values where appropriate can be found in Table 7. 
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Retrospective Cohort Studies in Athletes   
 Harris et al. (2012) conducted a retrospective cohort study on Hb AS related 
deaths in competitive athletes.  Participants were identified through a forensic 
database registry at the Minneapolis Heart Institute Foundation (MHIF).  This data set 
was created in order to compile data on death among young athletes playing 
organized sports.  The investigators gathered past data and also collected data    
Participants were included in the study if they were 39 years of age or younger at the 
time of death and if they were participating “in organized team or individual sports 
requiring regular competition, and placing a premium on excellence and 
achievement” at the time of death.  The database was used to identify sudden deaths 
in athletes between 1980 and 2010, resulting in 2,642 participants.  Of these, there 
were only 23 deaths related to sickle cell trait and all but 2 occurred in males.   
These 23 participants were between the ages of 12 and 22  years and made up 3.3% of 
the total African American study population.  Nineteen of the deaths were associated 
with football, 3 with basketball, and 1 with track.  Confirmation of Hb AS status was 
done through hemoglobin electrophoresis, solubility testing, or both.  These tests 
were conducted either premortem or during autopsy.  
 The authors also included data on environmental conditions during which death 
occurred.  Twenty-two of the participants died during training or conditioning while 1 
died during competition.  Seventeen of the deaths occurred between June and 
October, 2 deaths occurred at high altitude, and 20 happened while temperatures 
were 80° Fahrenheit or higher.  Four of the athletes had structural cardiac 
abnormalities, but these were determined not to be the major or primary cause of 
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death.  Rhabdomyolysis was found in 11 of these deaths, while it was only determined 
to be the cause of death in 5 of the remaining 2,619 deaths in the registry (Harris et 
al., 2012). 
 Harris et al. (2012) state that Hb AS deaths were more common among AA at 
100% vs. 37% (p-value <0.001).  Their data show that these 23 participants are 7% of 
the total 271 AA football players in the registry, which reflects the overall AA Hb AS 
carrier status rate of 8% in the U.S. population.  However, the results used for this 
conclusion are slightly flawed, as they actually represent just over 8% of the AA 
football players in the registry.  Unfortunately, they do not make it clear which 
comparison group they used to draw this conclusion.  They also note that Hb AS status 
was not known for all deaths found in the in the registry due to privacy restrictions 
and may have resulted in the lack of inclusion of all possible Hb AS deaths.  Harris et 
al. (2012) note that this may over-represent the risk of Hb AS related death as many 
more AA in the US should suffer from adverse health outcomes if these rates held true 
in the general population.  They suggest that a subset of Hb AS carriers is at a higher 
risk due to currently unidentified environmental, physiological, and genetic factors. 
Ultimately, the authors conclude that Hb AS is a risk during athletic competition and 
should be treated as such (Harris et al., 2012). 
 Boden et al. (2013) also utilized a retrospective cohort study to look at all 
fatalities among college and high school football players.  Participants were identified 
through reports of fatal episodes during organized school-sponsored sporting events 
gathered from national newspaper clippings, athletic trainers, national and state 
athletic organizations, and athletic coaches from July 1990 through June 2010.  The 
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authors classified injuries as occurring from trauma sustained during training, 
conditioning, and competition as a result of cervical fracture, cardiac failure, sickle 
cell trait, pulmonary embolism, asthma, brain injury, intra-abdominal injury, or heat 
illness.  The authors used a questionnaire to collect information weight, height, 
participation level, timing of injury, and position played.   They also gathered 
information on the weather on the days of deaths where Hb AS and heat death 
occurred.  They found a total of 243 deaths; all decedents were male (Boden et al., 
2013).    
 Boden et al. reported 11 Hb AS deaths, all of which occurred during training 
and conditioning, specifically during agility and sprinting drills.  These deaths were all 
found to occur between 1999/2000 and 2009/2010.  Interestingly, the authors state 
that risk of death from Hb AS complications during the second decade of the study 
was 9.7 times higher than that during the first decade.  This was a counterintuitive 
finding because, according to their data, all Hb AS related deaths occurred during the 
second decade of the study.  Temperatures on the day of death ranged from 44°F to 
93°F, with humidity between 50% and 100%.  Altitude was also highly variable, 
ranging from 48 to 2,116 feet above sea level.  Eight of the deaths occurred in 
southern states, 2 in mid-western states, and the location of 1 death was unknown.  
The authors found that in all types of deaths the odds ratio for death was higher 
among college level athletes than high school athletes with an odds ratio for college 
fatalities to high school fatalities of 66.6 (Boden et al, 2013).    
 Boden et al. (2013) state that it is not clear why the odds ratio for Hb AS 
related deaths among college level football players is so much higher than odds ratio 
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for high school level players, but speculate that this may reflect higher rates of AA 
players at the college level, more intense training in college, Hb AS awareness and 
diagnosis, or unknown factors.  They found that average temperatures and humidity 
were lower during fatal events for Hb AS than for heat related deaths, indicating that 
these factors may not be as important in the development of Hb AS crises.  They also 
state that Hb AS athletes had lower average BMI’s than those dying from heat related 
causes.  At the time of death, the participants had core body temperatures under 
105°F, pain in the low back and buttocks, and a rapid development of sickling 
symptoms without warning signs.  The authors note that their study is limited by the 
use of information from the public domain, underreporting of high school and college 
football deaths, and the lack of specific information on some of the fatalities.  The 
authors conclude by supporting the Hb AS testing of athletes and suggest that 5 of the 
Hb AS deaths may have been prevented had the coaches, trainers, and athletes been 
aware of the athletes’ Hb AS status (Boden et al., 2013).    
 A similar retrospective cohort study conducted by Harmon et al. (2012) looked 
at Hb AS-related sudden deaths among National Collegiate Athletic Association (NCAA) 
football players and discussed different screening methods and their cost-
effectiveness.  Participants were found using a database of athlete deaths that 
contains data from both the Parent Heart Watch (PHW) database and the NCAA 
Resolutions list.  The NCAA resolutions list is voluntary and the PHW database is 
updated through weekly internet searches to identify reports of sudden death and 
sickle cell anemia Hb SS in young people.  All participants were male and died 
between January 2004 and December 2008.  The authors cross-referenced NCCA 
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deaths found in the PHW database with the NCAA resolutions list and created a single 
database for their own use.  Any missing information was obtained through contact 
with athletic directors, athletic trainers, coroners, sports information directors, and 
Internet searches.  Demographic information was found in other NCAA reports 
(Harmon et al., 2012). 
 The authors found that there were 7,432 NCAA football athletes who carried Hb 
AS between 2004 and 2008.  There were 7,102 Hb AS carriers among black athletes 
and 331 among non-black athletes.  The authors estimated that approximately 7% of 
black NCAA athletes had Hb AS, while approximately 0.16% of non-black athletes 
carried Hb AS.  There were 12 exertional deaths, 5 of which were Hb AS related 
deaths, representing 42% of the exertional deaths.  Harmon et al. (2012) found that 
among football players of all divisions the relative risk of exertional death among 
those with Hb AS compared to those without Hb AS was 29.  Among division 1 football 
players, this was even higher at 37.  The authors found that Hb AS is associated with 
an increased risk of death in football players and argue that in order to prevent death 
in Hb AS carriers, especially those who play college level football, strategies to 
prevent and treat Hb AS crises are needed (Harmon et al., 2012).  They suggest, 
“screening to identify athletes followed by education, targeted modifications of 
training and conditioning, an acclimatization schedule, cessation of activity with any 
symptoms, and allowing Hb AS athletes to set their own pace” (Harmon et al., 2012).   
 In 1995, VanCamp et al. used a retrospective cohort design to examine 
nontraumatic deaths among high school and college athletes.  The National Center for 
Catastrophic Sports Injury Research (NCCSIR) data was searched for nontraumatic 
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deaths occurring between July 1983 and June 1993, as well as a news clipping service.  
The authors defined nontraumatic deaths as those with symptoms beginning during or 
within 1 hour following high school or college sporting events.  One hundred and sixty 
non-traumatic deaths were identified and complete autopsy data was available for 
126 of the deaths.  Seven of the 160 deaths were found to be from rhabdomyolysis 
and sickle cell trait, accounting for 5% of the non-traumatic deaths. Six of these 
deaths occurred in males and 1 in a female; all were AA (VanCamp et al., 1995).   
 Limitations to this study include underreporting of non-traumatic sports deaths 
occurring in the off-season and not related to athletics.  Additionally, autopsies were 
performed by multiple medical examiners, which could introduce interobserver 
biases.  Lastly, the authors twice state that 136 were used for the purpose of this 
study while 137 are reported in their tables.  The authors state that the 7 deaths due 
to rhabdomyolysis associated with Hb AS were not expected as Hb AS (at this time) 
was believed to be a benign condition that did not influence health outcomes.  They 
discuss recent studies reporting that Hb AS may be a key component in the 
development of exertional rhabdomyolysis in athletes, especially in well-muscled Hb 
AS athletes performing maximal exercises during preseason conditioning (VanCamp et 
al., 1995). 
 The last retrospective cohort study included in this review was undertaken by 
Maron et al. in 1996.  Maron collected cases of sudden death in athletes beginning in 
1985.  Data were also collected from the cardiovascular pathology registry of Baylor 
University Medial Center, news stories, the NCCSIR, and through reports and contacts 
with high schools and colleges.  Participants were included in the review if they were 
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under the age of 35 years, a competitive athlete, had available autopsy information, 
and showed no use of drugs in toxicological screenings after death.  The authors 
identified 158 deaths for inclusion from 1985 through 1995.  Twenty-four participants 
died from noncardiovascular conditions.  Among those dying from cardiovascular 
causes there were 12 deaths in individuals under 14 years, 83 in high school athletes, 
30 in college athletes, and nine in professional athletes.  Hypertrophic 
cardiomyopathy (HCM), which is when the heart muscle becomes thick, was found in 
48 individuals and was the leading cause of death in this study.  In 6 of these 48 
deaths there were comorbidities that contributed to death:  while only 1 of these 
deaths was associated with Hb AS.  The authors do not discuss the role of Hb AS in 
sudden death.  They state that of the 130 cases who had individual cardiac 
evaluations and standard preparticipation screenings only 2 of the cases were denied 
eligibility while only 6% of the cases were correctly diagnosed.  They conclude that 
preparticipation screening needs to be more rigorous in order to identify potential 
health risks and prevent sudden death in athletes.   
Retrospective Case-Series in Military Personnel                                                
 The earliest study included in this review was conducted by Jones et al. in 
1970.  It is a small retrospective case-series examining four deaths among African 
American military recruits at 1 training facility between March 1968 and February 
1969.  These deaths were the only four that occurred among African Americans at this 
facility during this time period.  All participants were reportedly healthy and in good 
athletic shape before reporting for basic training.  This particular training facility was 
located at an altitude of 4,060 feet above sea level.   Three cases were 21 years old 
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and 1 was 19 years old.  The recruits who were 21 years old all collapsed during their 
first day of training.  The 19-year-old recruit collapsed during his 21st day of training.  
Sickle cell status was confirmed upon autopsy in all cases.  Case 1 collapsed, but 
regained consciousness at the hospital where he complained of shortness of breath 
and faintness.  Within the hour he became hypotensive and combative and then lost 
consciousness.  He was treated for hyperkalemia and hypotension, but did not 
improve and died 24 hours after his initial collapse.  Case 2 fell ill while running 1 
mile and was resuscitated once he arrived at the medical clinic.  He also became 
hypotensive and died 25 hours after he collapsed.  In the third case the recruit 
complained of faintness, but continued participating in a 20-yard low crawl 
whereupon he passed out.  He was pronounced dead upon arrival at the medical 
clinic.  The fourth recruit complained of numbness in his legs and faintness.  He lost 
consciousness while running around the barracks, but regained consciousness and 
complained of leg weakness and pain.  He became apneic and died 8 hours after his 
initial collapse.  The authors proposed that the recruits all entered into sickling 
crises, which became fatal.  The authors believe the crises were caused by the arrival 
at a high altitude and moderate-to-severe exercise despite the recruits apparent good 
health.  Jones et al. (1970) conclude that under certain circumstances Hb AS can be a 
risk factor for sudden death (Jones et al., 1970). 
Retrospective Cohort Studies in Military Personnel 
 The first study discussing Hb AS and sudden death during physical exertion in 
military recruits was conducted by Kark et al. in 1987.  The retrospective cohort study 
was conducted to determine risk of Hb AS and age on sudden death among similar 
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populations:  recruits with Hb AS and those without.  Participants were all enlisted 
recruits between the ages of 17 and 34 years during the years of January 1, 1977 
through December 31, 1981.  Data on the recruits was gathered from the Defense 
Manpower Data Center and Accession Operations in the Department of Defense.  
Mortality data were identified through morgue logs, patient administration logs and 
files, and autopsy files from 17 hospitals serving 15 basic training centers.  Any 
participants who were transferred to civilian facilities were tracked through patient 
logs and outside records (Kark et al., 1987).   
 Recruits were divided into those with Hb AS and those without Hb AS as well as 
black and non-black groups.  Recruits were also grouped by unexplained and 
explained sudden death or non-sudden death.  In total, 62 deaths were identified.  
Among all Hb AS recruits there were 12 unexplained sudden deaths 1 explained 
sudden death in black recruits, and no sudden deaths either explained or unexplained 
in non-black recruits.  Among those without Hb AS there were 5 unexplained and 
explained sudden deaths each in black recruits, and in non-black recruits without Hb 
AS there were 11 unexplained sudden deaths and 8 explained sudden deaths.  Non-
sudden deaths only occurred in 3 black recruits without Hb AS and in 17 non-black 
recruits without Hb AS.  The unexplained sudden deaths of 13 black recruits with Hb 
AS were all exercise related.  Additionally, of the 42 sudden deaths in all groups, 40 
of them were exercise related (Kark et al., 1987).   
 The authors found the unexplained sudden death rate among Hb AS recruits to 
be 32.2 and among non-Hb AS recruits to be 1.2, resulting in a relative risk of 27.6 
with a wide confidence interval of (9, 100) that was statistically significant with a p-
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value < 0.001.  All sudden deaths among Hb AS carriers compared to all sudden death 
among non-Hb AS carriers resulted in a relative risk of 15 with a confidence interval 
of  (6, 38) and a p-value of <0.001.  Interestingly, the authors then subdivided these 
groups by age into the ranges of 17 to 18, 19 to 20, 21 to 22, 23 to 25, 26 to 30, and 
31 to 34.  Using these groupings Kark et al. (1987) found an increasing trend of death 
among Hb AS recruits as age increased.  This trend proved to be statistically 
significant with a p-value of 0.04.  There were no deaths among Hb AS carriers 
between the ages of 31 and 34 years, but the second oldest grouping had a relative 
risk of 95.1 with the youngest grouping having a relative risk of 12.9.  The authors 
note that this is due to an increasing rate of death as age increases while the pool of 
sudden unexplained death remained the same (Kark et al., 1987). 
 Kark et al. (1987) suggested that their results may not be generalizable to 
populations of athletes, those with advanced military training, or heavy-labor 
workers, and state that previous research has not examined large enough study 
populations to determine whether higher death rates occur in Hb AS carriers.  The 
authors found that Hb AS is not a risk factor for explained sudden death or non-
sudden death, but conclude that it is a risk factor for exertion-induced unexplained 
sudden death among military recruits (Kark et al., 1987).  
 The most recent study regarding Hb AS in military personnel was also a 
retrospective cohort study and was conducted by Eckart et al. in 2004.   The authors’ 
basic research question was to determine causes of nontraumatic death in military 
recruits.  Participants were identified through the Department of Defense Recruit 
Mortality Registry, which has records for every recruit death and autopsy.  
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Nontraumatic deaths were eligible for inclusion in this study if they were classified as 
idiopathic or from exertional heat illness, cardiac, exercise-related, vascular, or 
asthma and occurred at a military training site before initial training was completed 
and while the recruit had an enlisted status in the armed forces.  The study spanned 
25 years and included deaths occurring from 1977 through 2001.  A death was 
considered sudden if symptoms began and became fatal within 1 hour.  Of the 277 
deaths identified by the authors, only 126 were included in the study.  Participants 
were between the ages of 19 and 35 years and included 15 females and 111 males.  
The authors found 3 non-cardiac deaths from sickle cell crises.  However, there were 
12 exercise related deaths in which the decedent was an Hb AS carrier.  The authors 
state that Hb AS is associated with idiopathic sudden death when compared with 
other causes of death, resulting in a p-value of <0.001.  Ultimately, Eckart et al. 
(2004) found that Hb AS was associated with 27% of idiopathic sudden deaths, which is 
similar to data found by Kark et al. (1987).  However, as the study encompassed the 
recruit deaths used in Kark et al.’s (1987) study, the authors argue that it is not 
additional supporting evidence of the association (Eckart et al., 2004). 
Discussion for Exercise Deaths Systematic Review 
 Sickle cell trait is usually a benevolent condition that is not associated with 
adverse clinical manifestations in the general public or in the athlete population.  
Indeed, many Hb AS carriers have perfectly normal lives which allow them to engage 
in strenuous exercise and even military service.  However, it has become clear that 
the trait sometimes results in adverse health events during athletic or military 
training.  This review was undertaken to gather information on Hb AS deaths among 
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military and athlete populations and determine whether or not Hb AS individuals who 
engage in strenuous physical activities face an increased risk of death.  Evidence in 
this review showed that there were Hb AS related deaths in every sample, but that 
these were very rare.  This does suggest, however, that carrying Hb AS may result in 
an increased risk of ill health and possibly death during or immediately following 
strenuous physical activities.  The results of this review suggest that further research 
on the topic is warranted as not all Hb AS individuals face this increased risk and it is 
important to determine which environmental and genetic factors aide in this 
increased risk.    
 Although the genetic reason for the different clinical outcomes of sickle cell 
anemic patients is now better understood (different SNPs modify fetal hemoglobin 
production and result in different disease courses), the possibility that different SNPs 
may be the reason why some Hb AS carriers have a mild outcome while others suffer 
from sickling events has not been well explored.  An excellent recent review on the 
physiological response of Hb AS carriers during exercise asks why some Hb AS 
individuals collapse under stress, but does not raise the possibility that differences in 
these SNPs may explain these events (Connes et al. 2008).  
 Research on physical exertion among Hb AS individuals has recently focused on 
athletes for two reasons.  First, a number of sudden deaths have made media 
headlines over the last decade (Elseveth, 2013; George, 2011), and second, the armed 
forces have had protocols in place to identify and protect Hb AS individuals.  The U.S. 
Navy, Air Force, and Marines currently screen for Hb AS after accession.  The army 
screened for Hb AS until 1991, but no longer does.  Instead, it now restricts 
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individuals going into specialized placements by testing their hematocrit levels.  
These individuals are only screened for Hb AS and alpha-thalassemia if test results 
indicate they are anemic.  The Air Force tests Hb S levels among recruits with Hb AS 
and does not allow individuals who have levels higher than 45% of total hemoglobin to 
remain in the service.  Sickle cell trait individuals with less than 45% Hb S are allowed 
to choose whether to leave the Air Force or remain as enlisted military personnel.  
The Navy, by far, has the most proactive approach to Hb AS.  Naval recruits with Hb 
AS are given a red wristband to indicate that they are only allowed to perform light 
duty activities until their hemoglobin levels have been tested.  Once tested, those 
with Hb S levels above 45% are issued a reddish orange belt to wear while engaging in 
strenuous physical activities as well as red dog tags.  They are also counseled 
regarding risk of sickling crisis at high altitudes and without proper hydration and 
taught the symptoms of exertion-induced sickling.  However, Hb AS recruits are not 
counseled on the risk of exercise related sudden death (Mitchell, 2007; O’Connor et 
al., 2012).   
Strengths of this Review 
 A major strength of this study is its inclusion of studies with large sample sizes.  
These populations are also the best representation of Hb AS deaths in the U.S. over 
the last few decades as Hb AS was not added to the international classification of 
diseases index (ICD) as a cause of death until relatively recently and deaths in the 
general population may have been misclassified (Anonymous, 2011).  Additionally, the 
inclusion of articles published during any point in time allowed for more complete 
inclusion of articles pertinent to this review.    
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Limitations of this Review 
This study is limited in a number of ways.  To begin, it may not be an accurate 
representation of the available literature since articles were only eligible for inclusion 
if they had been published in English.  Although the search terms used were broad, 
they may not have revealed all articles eligible for inclusion in this study.  
Additionally, only the author reviewed articles for inclusion and scored them for 
methodological quality.  The use of multiple scorers may have resulted in the 
inclusion of different articles or the exclusion of ones reviewed.  Reviewers with a 
high inter-rater reliability would have helped this review achieve higher validity and 
reproducibility.  Articles that were not available for inclusion in this review are also a 
limitation.  The populations chosen for this review presents another limitation; 
military and sports populations are comprised of primarily very physically active and 
physically fit individuals who tend to be in their late teens to early 30’s.  As such, 
they may not accurately represent individuals with SCT and the risks they face with 
different lifestyles.  Further, many individuals in this study were male and thus both 
genders were not equally represented.  Gender may be a confounder that this review 
did not take into consideration.   
Limitations of the Studies Included in this Review 
 Limitations of this study stem largely from the individual limitations posed by 
each study included in the review.  The small sample of studies included is also 
potentially problematic as it does not fully represent all sudden death from Hb AS in 
the U.S. In fact, this is impossible due to differential diagnostic procedures in place 
throughout the U.S.  Furthermore, a deoxygenated state occurs upon death, which 
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can result in sickling.  This may skew results in both directions as some medical 
examiners dismiss this as a result of death while other may list it as the cause of 
death. 
Conclusion of Exercise Deaths Systematic Review 
Sickle cell trait has been linked to ill health and sudden death in carriers.  It is 
evident that it can no longer be considered a benign condition that does not affect 
health outcomes.  While not all Hb AS carriers experience ill health, they should be 
aware of their status and the fact that they may suffer adverse health events.  These 
events may be mild or severe and should be treated appropriately by medical 
personnel to minimize the amount of harm suffered by the patient.  Medical care 
providers, athletic trainers, and coaches should be educated on the risks and 
symptoms so that Hb AS carriers can be treated properly upon collapse and increase 
their chance of surviving a sickling crisis without lasting health effects.  
It is almost as if Hb AS athletes have been medically ignored; they are healthy 
college athletes who might 1 day collapse and die.  It is obvious that not all Hb AS 
individuals are the same, and that athletic departments need to be aware that some 
are at greater risk than others.  Though many studies have examined hemorheological 
changes between those with hemoglobinopathies and those without, it is still not well 
understood what precipitates sickling changes in those with Hb AS.   Sickle cell trait is 
associated with an increased risk of sudden death during and immediately following 
exercise.  It is time that it is recognized as a cause of poor health, a risk factor for 
sudden death, and as a significant burden for some carriers.  
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Alabama 3 South Dakota 0
Alaska 1 Tennessee 2
Arizona 2 Texas 6
Arkansas does not record SCT as a COD Utah 0
California does not record SCT as a COD Vermont 0
Colorado 13 Virginia 4
Connecticut 1 Washington 1
Delaware no data Washington, D.C. 0
Florida 10 West Virginia 0
Georgia no data Wisconsin no data
Hawaii no data Wyoming 0
Idaho 0 Total 74
Illinois 2 *Not all states record deaths from SCT. 
Indiana 2 $Data was not available for the full time period in every state.
Iowa 1
Kentucky 0
Kansas 0
Louisiana no data
Maine 0
Maryland 1
Massachusetts 1
Michigan does not record SCT as a COD
Minnesota 3
Mississippi 3
Missouri does not record SCT as a COD
Montana 0
Nebraska 0
Nevada 0
New Hampshire 1
New Jersey 4
New Mexico 0
New York 4
New York City 3
North Carolina 5
North Dakota 0
Ohio no data
Oklahoma 1
Oregon does not record SCT as a COD
Pennsylvania no data
Rhode Island no data
South Carolina does not record SCT as a COD
Tables and Figures 
Table 4. Count of Hb AS as a Reported Cause of Death in all U.S. States between 
2000-2011*$ 
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Search Terms Used
sickl* cell trait athlet* exercis* physical
sickl* and cell and trait and athlet*
sickl* and cell and trait and exercis*
sickl* and cell and trait and physical
sickl* and cell and athlet*
sickle and cell and exercis*
sickl* and cell and physical
Table 5. Search Terms Used to Identify Articles Potentially Eligible for Inclusion in    
     this Review 
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Figure 3. Geospatial representation of Hb AS related deaths by U.S. state*   
*All deaths occurred between 1999 and 2010. 
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         








 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Flow chart detailing articles identified for inclusion this review  
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Hypotheses (maximum possible = 1) 
• The hypothesis/research question of the study not clearly described = 0 
• The hypothesis/research question of the study clearly described = 1 
Study Type (maximum possible = 5) 
• Systematic Review = 5 
• Randomized Control Trial = 4 
• Cohort Study = 3 
• Case-Control = 2 
• Case Series OR Cross Sectional = 1 
Sampling (maximum possible = 3) 
• Sample Source and Size  
• Routine data = 0 
• Sample size less than 50 = 1 
• Sample size more than 50 = 2 
• Selection Criteria 
• Selection of cases/controls/population not well described = 0 
• Selection of cases/controls/population well described = 1 
Methodology (maximum possible = 3) 
• Inclusion of other variables: 
• Age = 1 
• Race = 1 
• Hb AS Status = 1 
Statistical Analyses and Results (maximum possible = 5) 
• Statistical Analysis (2) 
• Statistical methods not described = 0 
• Statistical methods clearly described = 1 
• Statistical outcomes (2) 
• Statistical outcome not clearly reported = 0 
• Some statistical outcomes clearly reported (e.g. CI’s but not P-values) = 1 
• Statistical outcomes clearly reported (e.g. CI’s and P-values) = 2 
• Results (1) 
• Research questions/hypotheses not clearly answered/tested = 0 
• Research questions/hypotheses clearly answered/tested = 1 
 
Maximum Score = 17 
 
Figure 5. Methodological quality scoring sheet used to assess the studies included in 
this review 
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Methods 
  
Recruitment 
 Participants were eligible for inclusion in this study if they were over the age 
of 18, male, had tested positive for Hb AS, and had played organized football at some 
point in their lives.  Participants were recruited via Facebook, Twitter, e-mail, phone 
calls, and word of mouth.   During the first phase of recruitment a Facebook page for 
Hb AS carriers was created.  Through the page the authors “friended” multiple sickle 
cell community, awareness, and advocacy groups.  The also used this medium to 
communicate with football groups in order to inform them about the study. No 
participants were found through these means, though many people shared personal 
experiences of pain and sickling crises with the author that were used as supporting 
evidence for our study.  The website address can be found in Appendix 2.  No 
participants or information was gathered through twitter. The second phase of 
recruitment consisted of e-mails sent out on the behalf of the authors to team 
physicians for collegiate football players containing a recruitment letter and 
promotional flyer.  The third phase of recruitment included phone calls to all Division 
1 NCAA football teams.  The next phase included phone calls to Division II and III 
schools.  The fifth phase of recruitment consisted of e-mails to all historically black 
colleges and universities (HBCUs).  All phases of recruitment were ongoing and 
overlapped once they were initiated.   
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 In early summer 2013, the author was able to register the study on the website 
www.ClincialTrails.gov, which provided a small measure of exposure for the study.   
In July of 2013, the author connected with a team physician at the University of 
Washington, Dr. Kim Harmon, who had recently published a paper on the risk of Hb AS 
in football athletes.  Dr. Harmon sent e-mails on the authors’ behalf to trainers and 
team physician in the Pacific-12 Conference.  Data for this thesis is in phase 1 of the 
study and is purely descriptive. 
 In July and August of 2013, the authors of this paper we able to partner with 
the Sickle Cell Foundation, who have agreed to help with recruitment for phase 2 of 
this study.  With their assistance, the authors believe that they can recruit a total of 
100 participants.  All participants from phases 1 and 2 will undergo genetic testing to 
determine whether or not they carry SNPs associated with increased levels of Hb F 
and their Hb S haplotype.  Using this information the authors hope to examine 
whether or not Hb S haplotype and genetic modifiers for HPFH and high levels of Hb F 
are associated with better and worse health outcomes.  
Phase 1 – Survey Data 
 Packets containing all data collection materials and consent forms were mailed 
to participants once they agreed to participate in the study.  Data for phase 1 
consisted of a set of clinical variables gathered through a survey completed by the 
participant.  A copy of the survey can be found in Appendix 3.  Data were collected on 
the variables of age, height, weight, football position played, whether or not the 
athlete felt he maintained adequate hydration during training and conditioning, 
where or not he had experienced sickling crises, heat illness, or dehydration, and 
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location of these episodes.  Participants were given the option of providing their 
medical records to our team clinician, Dr. Eduardo Gonzalez, though at this juncture 
no medical records have been received.  
Phase 2 – Genetic Analyses 
  Participants collected or will collect a genetic sample via a buccal swab and 
send the sample directly to the School of Human Evolution & Social Change at Arizona 
State University.  There, Dr. Anne Stone will oversee all genetic typing.  She states,  
DNA will be extracted following standard procedures, and SNPs involved 
in fetal beta globin regulation will be typed (Wajcman and Riou 2009).  
DNA will be extracted using standard phenol-chloroform method 
(Sambrook and Russell 2001).  The DNA will then be used to assess three 
SNPs that have been linked to fetal globin production: Rs4671393 in 
BCL11A, Rs9402686 in HB S1L-MYB, and rs7482144 downstream of HBG1 
(Galarneau et al. 2010). For each SNP, the polymerase chain reaction 
(PCR) will be used to amplify the DNA containing the SNP. For rs7482144, 
the primers and PCR conditions used are as previously published (Sutton 
et al. 1989), while new primers were designed for the other two SNP 
regions. The PCR products containing Rs4671393 and rs7482144 are 
digested with the restriction enzymes BtsIMutI and Xmn1, respectively, 
to detect the presence or absence of the SNP.  For both restriction 
digests, the products will be visualized on a 2% agarose gel with a 1 kb 
ladder size standard.  The PCR products containing Rs9402686 in the HB 
S1L-MYB gene region are sequenced in the ASU core laboratory using the 
ABI 3100 sequencer.  Sequence data will be analyzed using SeqMan Pro 
in the Lasergene core suite (DNAstar). 
 
 Results from the DNA typing will be sent to the author, who will correlate the 
results with the surveys collected from participants and will be analyzed by the team 
clinician, Dr. Eduardo Gonzalez.  Fisher’s exact test will be used to test associations 
between haplotypes, SNPs, and health outcomes.  Fisher’s exact test is particularly 
well designed to deal with low-frequency events such as we anticipate in this project 
and will be used to test the hypothesis that SNPs associated with production of Hb F 
influence health outcomes.  We will perform a logistic regression analysis in which the 
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dependent variable is the dichotomous variable “presence of adverse health 
outcomes” and “absence of adverse health outcomes”.  During phase 1 the predictive 
model will include only clinical variables.  During phase 2 the predictive model will be 
expanded to include clinical variables and SNP genotypes.  Odds ratios comparing the 
occurrence of adverse health outcomes between SNPs associated with the production 
of Hb F will be calculated.  
Statistical Analyses 
 Given the small sample size, the author was only able to run Fisher’s exact 
tests to compare survey responses.  Analyses were run using SAS 9.3.  All SAS codes 
used can be found in Appendix 4.  
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Results  
Facebook 
 Initial results were gathered through personal and public communications on a 
Facebook page the author created titled “Carriers of Sickle Cell Trait”.  
Communication with 5 individuals from the U.S., Uganda, and the United Kingdom 
(U.K.) add support to the proposition that Hb AS carriers suffer poorly explained ill 
health.  A woman in the U.S. reported that she is physically active, rides her bike 3 to 
4 miles every other day and walks the same distance 3 to 4 times a week, but has 
unexplained pain in her arms and legs in cold weather, especially during the winter.  
A different woman in the U.S. states that she suffers from bone pain, particularly in 
her back, which becomes so strong she is often hospitalized and put on prescription 
painkillers.  Another Hb AS individual in the U.S. informed the author that he suffers 
from body pain frequently, but his doctors are unable to explain it.  He has asked his 
doctors about a connection to his Hb AS status, but they have dismissed it and told 
him that it does not cause health issues.  A woman from the U.K. and her 2 sons are 
all Hb AS carriers.  Both of her sons suffer frequent pain and fatigue.  Sometimes her 
youngest son cannot get out of bed due to the pain, but doctors have been unable to 
explain it.  During an emergency room visit for 1 of her sons she informed the doctor 
that her son had Hb AS and he responded by simply stating that they were not black.  
The woman has had unexplained health issues involving her spleen and liver.  
Interestingly, she also reports pain in her joints during cold weather.  Lastly, a 
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Ugandan man reports that he has had unexplained pain for years.  He has undergone 
50 diagnostic tests in an effort to find the source of his symptoms, but the only thing 
he has tested positive for has been Hb AS (Personal Communications, 2012; Personal 
Communications, 2013). 
Surveys 
 Between October 2012 and June 2013, 14 participants were recruiting for the 
study.  An additional 6 participants have been recruited between August and 
September 2013, thanks to the help of Dr. Kim Harmon. All were included in the data 
used for this thesis.  The author received 20 surveys while 21 samples were received 
at the SHEMC.  Participant number 4 returned a sample to the lab, but did not return 
a survey.  The vial containing his sample was, however, empty upon receipt leaving 20 
participants.  The data set containing deindentified responses can be found in 
Appendix 5. 
 Fourteen of the participants felt that they maintained a safe and healthy level 
of hydration during training, 3 participants felt that they did not, 1 participant did 
not know whether or not he kept this level, and 2 participants did not answer.  
Fourteen participants felt they were able to maintain an adequate level of hydration 
during athletic competitions, 4 felt they were unable to maintain an adequate level, 
and 2 participants did not respond.   Twelve of the participants reported that they 
had unhealthy dehydration (UD) at some point, while 8 reported that they had not 
experienced UD.  Symptoms reported by the 12 participants who responded positively 
to UD include:  dry, sticky mouth, sleepiness or being tired, thirst and/or extreme 
thirst, decreased urine output, headache, dizziness or being lightheaded, rapid 
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breathing, and rapid heartbeat.  Among these participants the frequency of UD varied 
from 1 to 100 experiences.  One participant responded that he felt unusually 
dehydrated 10% of the time and 1 responded that it happened 2 to 3 times a week.  
Unusual dehydration was experienced in Pennsylvania, New York, South Carolina, 
Washington, California, Florida, and Colorado.  Two participants responded that they 
had not experienced UD at any point, but 1 indicated that he had experienced 
dizziness or lightheadedness twice and the other replied that he did not know what 
symptoms he had experienced.  It is unclear if they experienced symptoms, but were 
unaware that they had been dehydrated, or did not read the instructions clearly and 
skip this question as instructed when answering “no”.   
 Two participants had been diagnosed with heat illness (HI) at some point, 17 
participants had never been diagnosed with HI, and 1 participant did not answer.  The 
2 participants who had experienced HI had each been diagnosed during early season 
training.  One participant who had not experienced HI replied that he had been 
diagnosed once, and another responded that he did not know how many times he had 
been diagnosed.  The 2 participants who had HI experienced symptoms of hard, tense 
muscles, weakness, fatigue, headache, excessive thirst, and agitation.  Three 
participants who had not been diagnosed with HI reported that they had experienced 
similar symptoms or that they did not know or preferred not to answer what 
symptoms they had experienced.  One participant with HI replied that the intensity of 
his workout immediately preceding their episode of HI was very hard while the other 
preferred not to answer.  Four participants indicated the intensity of their workout 
before diagnosis with HI, but stated that they had not ever been diagnosed with HI.  
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The participants who had been diagnosed stated that the episodes occurred in 
Washington and South Carolina.  Two other participants who had not had HI reported 
that they had experienced episodes in Washington (this participant reported he had 
experienced HI twice in this location) and Colorado, while 2 other reported that they 
preferred not to answer where they had experienced HI.   
 Section four of the survey asked personal opinion questions about the 
participants’ experiences in comparison with their peers.  Fifteen respondents said 
that they did not feel their muscle pain lasted for longer periods of time than their 
peers’, 2 responded that they did feel their pain lasted longer, and 3 did not answer.  
Four participants felt that it took their muscles longer to recover from workouts or 
training than their peers’, 12 felt this was not the case, 3 participants did not answer, 
and 1 preferred not to answer.  When asked if they felt they experienced higher 
levels of muscular pain in comparison to their peers, 13 participants responded that 
they did not feel this was the case, 2 felt they did experience higher levels of pain, 2 
did not know, and 3 did not answer.  The 2 respondents who felt they had 
experienced more pain than their peers indicated that this pain was mild or moderate 
in comparison.  Three participants who did not feel they had higher levels of pain 
indicated that they did not know or preferred not to answer their level of pain in 
comparison to their peers’. 
 Five of the 20 participants reported that they had been diagnosed with 
exertional sickling (ES), with the remaining 15 responding that they had never been 
diagnosed with ES.  The 5 participants with ES reported symptoms of leg pain or 
weakness, low back pain or weakness, muscle cramping that spread throughout their 
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body, and rapid breathing.  One participant preferred not to answer, and 1 
participant who had not been diagnosed with ES also indicated that he preferred not 
to report what symptoms he had. The 5 participants who responded yes indicated that 
they had experienced ES 1, 3, 7, 8, and a “few” times.  These episodes occurred in 
South Carolina (4 of the 5 participants) and Washington.  
 Respondents were also asked what symptoms they had experienced during 
workouts or training from a compiled list of all symptoms from HI, US, and ES.  
Eighteen of the participants responded to this question while 2 chose not to answer.  
Among the symptoms experienced were:  a dry, sticky mouth, sleepiness or tiredness, 
thirst or extreme thirst, rapid breathing, fatigue, decreased sweating, breathlessness, 
low back pain or weakness, decreased urine output, headache, dizziness or 
lightheadedness, low blood pressure, rapid heartbeat, hard or tense muscles, nausea 
or vomiting, fainting, agitation, weakness, confusion or anxiety, hot, flushed, or dry 
skin, blood in urine or stool, increased body temperature, convulsions or seizures, 
severe or debilitating heat cramps, cold and clammy skin, leg pain or weakness, and 
muscle cramping that spread throughout the body.  One participant indicated that he 
preferred not to answer this question, did not know what he had experienced, and 
had experienced “other” symptoms.  He did not indicate what these “other” 
symptoms were, as we had requested if choosing this option.  These symptoms were 
experienced in South Carolina, Pennsylvania, Florida, California, New York, 
Washington, and Colorado.  One of the participants who chose not to answer 
indicated that he did not know where he had not experienced symptoms.  Two 
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participants each responded that they did not know where they had experienced 
symptoms or preferred not to answer.   
 The remaining questions on the survey dealt with demographic information 
such as height, weight, biological background, racial self-identification, whether they 
smoked or had asthma, whether they had any hemoglobinopathies besides Hb AS, 
average resting blood pressure, and the position they played on their football team.  
One participant did not answer any demographic questions.  Nineteen participants 
weighed between 115 pounds and 345 pounds, with a mean weight 201 pounds.  
However, 17 of the participants weighed within a 106 pound range, from 157 263 lbs.  
Participants’ height ranged between 61 and 78 inches, with a mean height of 71.72 
inches.  All participants were over the age of 18, with an age range of 18 to 24 years 
with an average of age of 19.9 years.  None of the 19 participants who responded 
reported that they had asthma; 18 stated that they did not smoke, and 1 indicated 
that he preferred not to answer if he smoked.  Only 1 participant knew his resting 
blood pressure, which was 120/80 mmHg.  Nineteen participants responded that they 
did not have any other hemoglobinopathies besides Hb AS. 
 Five participants play(ed) safety, 2 cornerback, 3 outside linebacker, 2 
defensive end, 2 wide receiver, and 1 each defensive tackle, tight end, quarterback, 
and fullback/running back.  One safety also played cornerback, and 1 defensive end 
also played tight end.  Seven participants did not know their biological background, 2 
reported that their family was from the Middle East and North Africa, 3 said that they 
were of North American of African descent, 3 stated that they were of Caribbean of 
African descent, and 5 did not respond.   One respondent who indicated that he was 
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Caribbean of African descent also marked that his biological background included both 
Caribbean of Northern and Southern European descent.   When asked how they self-
identify racially, 17 participants indicated that they say they are “Black, African 
American, or Negro”, 1 replied that he is “Cuban”, and 2 did not respond. One of the 
“Black, African American, or Negro” respondents also identifies as “American Indian 
or Alaska Native”, and the “Cuban” also identifies as “White”. 
 Of the 12 participants who experienced UD, only 1 of them was also diagnosed 
with HI. Two of these 12 were also diagnosed with ES.  One of the participants 
diagnosed with HI was also diagnosed with exertional sickling.  None of the 
participants reported experiencing all 3 health issues.  These results can be found in 
Table 8.  All tables and figures for this section can be found at the end of this chapter 
The frequency of ES, UD, and HI were compared with each other and with the 
variables adequate level of hydration (ALHY), safe and healthy level of hydration 
(SHLHY), muscle pain severity in comparison to peers (COMPPN), recovery time in 
comparison with peers (COMPRECV), and muscle pain duration in comparison to peers 
(COMPMPD) in individuals who experienced ES, UD, and HI.  To determine whether or 
not there were associations between the variables SHLHY, ALHY, COMPPN, 
COMPRECV, and COMPMPD they were all compared using Fisher’s Exact Tes 
 Given the small sample size, no significant results were expected.  However, of 
the 20 tests run, the comparison of COMPRECV by COMPMPD produced a statistically 
significant right-tailed p-value > F of 0.0049.  The results of this test indicate that the 
probability of the player feeling his muscle pain lasts longer than his peers’ is greater 
among those who feel it takes their muscles longer to recover than their peers’ than 
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among those who do not feel it takes their muscles longer to recover than their peers.  
In other words, players who feel that their muscles take longer to recover compared 
to their peers were significantly more likely to feel their muscle pain lasts longer than 
their peers.  This result can be found in Table 9.  Results from all tests can be found 
in Appendix 6. 
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Discussion 
 
Genetic Analyses of Hb F  
 
 Hemoglobin requires 2 α-globin amino acid chains and 2 β-globin amino acid 
chains. The beta chain is encoded by a cluster of genes on chromosome 11 that are 
each turned on during specific stages of development (Fritsch et al. 1979; Mahajan et 
al. 2007).  During embryonic development the epsilon gene (Hb E1) is active, which 
causes 2 pairs of identical chains.  The chains created by the epsilon gene are alpha-
like and beta-like.  During fetal development the 2 gamma genes (Hb G2 and Hb G1) 
are active and after birth 2 adult genes, beta (Hb B) and a minor delta (Hb D) gene 
are active.  Eventually, the Hb D chain is replaced by an adult alpha chain (Hb A), 
resulting in the “normal” adult phenotype Hb AA, as discussed in the introduction.  
The chains created throughout development function similarly to the adult alpha and 
beta chains in order to ensure smooth transition to adult hemoglobin.   As the 
successive genes are turned on, the genes active during the earlier stage are turned 
off. While each beta globin gene is rather short, the beta globin cluster is ~60 kb long 
and has a recombination hotspot in the midst of it (just 5’ of the Hb B gene) 
(Antonarakis et al. 1982; Wall et al. 2003).  The diversity in the region has been 
assayed using 6-15 RFLP sites spread over 45-60 kb (e. g. Lapoumeroulie et al. 1992; 
Pagnier et al. 1984) as well as through resequencing (Galarneau et al. 2010).  Among 
those with Hb SS, more benign clinical profiles were initially linked to specific 
haplotypes in the beta-globin cluster (Nagel et al. 1985), but have recently been 
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linked to specific SNPs that influence Hb F expression (Galarneau et al. 2010; Uda et 
al. 2008).  Specifically, three SNPs that have been linked to higher expression of the 
fetal (HBG1 and HBG2) genes in the β-globin gene cluster will be investigated.  These 
SNPs include Rs4671393 in BCL11A, Rs9402686 in HB S1L-MYB, and rs7482144 
downstream of HBG1 (Akinsheye et al. 2011; Platt et al. 1994; Powars et al. 1984). 
Ender et al., 2011; Green & Barrall, 2011; Sankaran et al., 2008; Sheehan et al. 2013; 
Stone, 2013; Thein et al., 2007).  
Hb F Level Differences among Hb AS Haplotypes 
 For many years, better clinical outcomes among SCD individuals were thought 
to be tied to the sickle haplotype they carried.  Sickle cell disease individuals 
homozygous for a haplotype showed that there was stratification in Hb F levels and 
clinical outcomes among four of the five haplotypes.  Specifically, the Saudi 
Arabia/India (SAI) haplotype had the highest Hb F levels and the best outcomes, 
followed by Senegal, Benin, and Bantu.  Ngo et al. (2011) report that the SAI and 
Senegal haplotypes usually have Hb F levels between 11% and 21%.  In comparison, 
Maier-Redelsperger et al. (1998) report that those with the Senegal haplotype usually 
have Hb F levels of 5.5% + 0.8%, those with the Bantu haplotype have Hb F levels of 
4.3% + 4.1%, and those with the Benin haplotype have Hb F levels of 3.3% + 1.6% 
(Maier-Redelsperger et al., 1998; Ngo et al., 2011; Steinberg & Sebastiani, 2012; 
Texiera, 2003;).   
 Fetal hemoglobin may be the most important modifier of clinical outcomes in 
HB AS and SCD.  Higher Hb F levels are associated with fewer and less severe pain 
episodes in Hb SS individuals.  This is due to the fact that increased Hb F production 
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compensates for lost Hb A production and helps minimize the number of cells that can 
sickle in response to stressors.  Levels of Hb F in Hb AS carriers are generally between 
15% and 35%.  Presence of fetal hemoglobin itself is not enough to mitigate sickling 
symptoms, and studies have not been able to determine exact levels of Hb F that are 
protective.  Levels of Hb F over 20% to 30% have been shown to be the most 
protective.  Non-F cells survive for approximately 2 weeks while F cells survive for 
approximately 6 weeks.  Additionally, F cells with higher Hb F levels survive longer 
than their counterparts with lower Hb F levels and those with higher F cell levels have 
lower non-F cell survival rates.  This differential erythrocyte survival rate can lead to 
increased Hb F levels.  Lower Hb F levels are tied to painful crises and acute chest 
syndrome.  Unfortunately, high Hb F levels can also cause ill health and are 
associated with silent cerebral infarcts, splenic sequestration, and dactylitis 
(inflammation of an entire finger or 2, which can be painful) (Adekile et al., 2007; 
Akinsheye et al., 2011; Bailey et al., 1991; Bhatnagar, 2013; Charache & Conley; 
1969; Ender et al., 2011; Forget, 1998; Franco et al., 2006; Jacob & Raper, 1958; 
Marcus et al., 1997; Ngo et al., 2011; Powars et al., 1984; Powars et al., 1989; 
Sheehan et al., 2013; Steinberg & Sebastiani, 2012; Whyte et al., 2013). 
 Levels of Hb F are influenced by many factors including, but not limited to, 
transcription factors, genetic elements linked to the β–globin gene cluster, age, α-
globin gene number, β-globin (Hb AS) haplotypes, chromosome remodeling activities, 
and kinetics of erythroid cell differentiation. It is also somehow linked to the X 
chromosome, as females often have higher levels than males.  In addition, Hb F levels 
are affected by comorbidity with other hemoglobinopathies such as alpha thalassemia 
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(Adekile et al., 2007; Adekile & Huisman, 1993; Ma et al., 2007; Marcus et al., 2007).  
An early study by Chang et al. (1995) found that the F cell production locus (FCP) 
located at Xp22.2.-22.3 was the most important genetic factor influence Hb F levels 
among SCD individuals.  However, they state that their study was unable to account 
for 50% of Hb F production variation. 
Hemoglobin Levels as Sickling Event Modifiers 
 Sickling episodes among Hb AS individuals may be influenced by their Hb S 
levels.  Kennedy et al. (1985) found that among military personnel there were no 
differences in Hb S level for certain outcomes, but that hematological characteristics 
differed among some groups.  Participants were divided into groups of Hb S < 30, 30 < 
Hb S < 35, 35 < Hb S < 40, and Hb S > 40.  Statistically significant differences were 
found between the groups on the variables of age (p = 0.01), mean corpuscular 
volume (p = 0.01), and hemoglobin concentration (p = 0.002).  Age was found to be 
associated with outcomes of hypertension (p = 0.000), myocardial infarction (p = 
0.0002), and, CVA (p = 0.0003).  However, the authors state that no relationship was 
found between Hb S level and vaso-occlusive crisis.  The authors suggest that a larger 
study be conducted to rule out the possibility that relatively rare outcomes such as 
thrombophlebitis, pulmonary embolism, and hematuria were not associated with Hb S 
level simply due to chance.  Kennedy et al. (19855) conclude, “Regardless of Hb S 
level, this and other studies suggest that Hb AS in black men is a benign 
condition”(Kennedy et al., 1985).  
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Sickling and Pathophysiological Differences During Exercise 
 The association between physical exertion, Hb AS, and sudden death remains 
unclear.  It does appear that intensity and speed of workouts, especially maximal 
exertion exercise, and inconsistent training can precipitate a sickling crisis, with 
sickling levels usually involving between 1% and 25% of erythrocytes.  Studies have 
been conducted on physiological responses in Hb AS individuals in comparison to Hb 
AA individuals and also those with Hb AS and alpha thalassemia.  These studies have 
included hemorheological and oxygen saturation responses, but have provided 
contradictory results.  An early study by Weisman et al. (1988) looked at 
cardiopulmonary and gas exchange responses in young and healthy Hb AS individuals.  
The study showed no statistically significant differences in cardiopulmonary response 
among Hb AA and Hb S individuals at rest, peak incremental testing, or steady-state 
exercise testing.  In fact, the only difference the authors observed was in the amount 
of oxygen consumed between groups during testing.  Monchanin et al. (2005) also 
conducted a study where they found maximal exercise performance did not differ 
between Hb AS and HbAA individuals.  However, they do state that Hb AS carriers are 
more likely to suffer hemorheological alterations than their peers.  Gozal et al. (1992) 
conducted a study to determine whether or not repeated bouts of short, maximal 
exertion affected their exercise performance.  They concluded that among highly 
trained Hb AS individuals repeated anaerobic and aerobic maximal exercise exertion 
did not affect exercise performance or recovery, though Hb AS participants were 
found to have lower blood lactate levels.  Chirico et al. (2012), on the other hand, 
tested oxidative stress among Hb AS and Hb AA at rest and post-exercise.  They found 
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no difference in oxidative stress between the groups, but sate that after exercising Hb 
AS carriers experience higher levels of oxidative stress, especially among those who 
do not train regularly (Chirico et al., 2012; Connes et al., 2008; Eichner, 1993 & 
Eichner, 2010; Ferster & Eichner; 2012; Kerle and Nishimura, 1996; Mitchell, 2007; 
Monchanin et al., 2005; Ramirez et al., 1976; Weisman et al., 1988).   
 Although Hb AS is often considered a benign condition, studies have shown that 
it can result in adverse health outcomes.  In 1978, Dr. David Sears compiled literature 
regarding diseases associated with Hb AS.  Literature shows that there is likely an 
increased risk for bacteriuria and pyelonephritis during pregnancy, glaucoma 
secondary to hyphema, renal medullary cancer, venous thromboembolism, hematuria, 
splenic infarction at high altitude, bacteriuria, and hyposthenuria with Hb AS 
comorbidity.  The author suggests that Hb AS may also be associated with avascular 
necrosis of bone, complicated migraine, proliferative retinopathy, increased fertility, 
abnormal physical properties of stored red cells, reduced urinary filtration fraction, 
decreased birth weight of babies born to mothers with Hb AS, intravascular sickling 
with strenuous exertion, and delayed skeletal maturation (Eichner, 1993; Kerle and 
Nishimura, 1996; Rodgers, 1988; Sears, 1978; Tsaras et al., 2009). 
 Factors that may increase the risk of sudden sickling events in Hb AS individuals 
include dehydration, increased intercurrent infection, hypothermia, temperature, 
altitude, acidosis, increased blood viscosity, exercise intensity, and local hypoxia.  
Studies have shown that even at sea level, maximal exertion exercise results in 
sickling, though it is usually involves less than 1% of erythrocytes.  Conversely, Martin 
et al. (1989) showed that at an altitude of 1,270 meters above sea level sickling can 
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occur at rest, increases during exercise, and increases significantly under conditions 
replicating 4,000 meters above sea level.  According to Loosemore et al. (2012), 
sickling deaths are often the results on sepsis due to functional hypersplenism, acute 
end-organ damage, heat stroke, disseminated intravascular coagulation, VOC, cardiac 
arrhythmia, multiorgan failure, renal failure, or a combination of these events 
(Eichner, 2010; Loosemore, 2012; Martin et al., 1989; Mitchell, 2007; Ramirez et al., 
1976; Tsaras et al., 2009).   
 Several studies suggest that Hb AS is related to increased risk of sudden 
exertional death (Chirico et al., 2012; Loosemore et al., 2012; Mitchell, 2007; 
Ramirez et al., 1976).  Since 2000, there have been 16 deaths among NCAA Division I 
football players, all of which occurred during conditioning and none of which occurred 
during game play.  Although Hb AS only affects 3% to 4% of the NCAA Division I 
football players, exertional sickling was responsible for 10 of these 16 deaths.  These 
deaths produce a 16 to 21 fold excess risk of death in this group.  As Eichner (1993), 
poignantly states, “Athletes – with Hb AS or not – should train wisely, stay hydrated, 
heed environmental stress and early symptoms, and never charge recklessly into 
heroic exercise. It’s not worth dying to make the team.”    
NCAA and Mandatory Testing for Hb AS 
 In 2010, the NCAA made Hb AS testing mandatory for all Division I athletes.  
This program was the result of a lawsuit filed by the family of Dale Lloyd, Jr., a 19 
year old who was a freshman football player at Rice University.  Lloyd experienced a 
sickling crisis associated with exertional rhabdomyolysis and died in 2006.  The 
screening program, which is the largest instituted since 1970’s, became a hotbed for 
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debate, with many people arguing that it was unnecessarily discriminatory.  Many 
feared that the discrimination found in earlier screening initiatives would be 
inadvertently replicated under NCAA screening.  Sickle cell trait carriers in the 
military were restricted from certain duties, and Hb AS screening among the general 
public led to insurance discrimination among carriers.  In addition to this, early 
programs propagated misinformation regarding the presence and outcomes associated 
with SCD and Hb AS.  It has also been suggested that this testing will pave the way for 
future genetic testing and potential discrimination.  Students can opt out of testing by 
providing earlier test results or signing a waiver releasing their university and the 
NCAA from all legal liability in case of Hb AS-related adverse clinical outcomes.  Many 
feel that the screening program is merely a legal tactic to avoid future lawsuits.  
Interestingly, although all newborns in all 50 states are tested for Hb AS, these results 
may never reach the parent or are not well-explained.  If parents are given the results 
they are often told the condition is benign and are not counseled on potential health 
risks (Bonham et al., 2010; Koopmans et al., 2011; O’Connor et al., 2012; NCCA 
Research Committee, 2012; Tarini et al., 2012). 
 Since 2012, the NCAA has made Hb AS-testing mandatory in all divisions, though 
players may still opt of out screening.  Those testing positive for Hb AS are offered 
genetic counseling so that they may make more informed health choices regarding 
their athletic pursuits, personal health, and family planning.  A study by Tarini et al. 
(2012) estimated that among NCAA Division I schools, this screening program would 
prevent 7 deaths over a ten year period; at a ratio of 1 death prevented per every 
141,181 student athletes screened. The authors discuss the prevention strategies 
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suggested by the NCAA, but note that these strategies are difficult to enforce, 
especially given the “pressure to play” atmosphere present in sports (Bonham et al., 
2010; Koopmans et al., 2011; O’Connor et al., 2012; NCCA Research Committee, 2012; 
Tarini et al., 2012).  
 Koopmans et al. (2011) conducted an interesting study surveying pediatrician’s 
attitudes and concerns regarding Hb AS testing in athletes.  Most respondents were 
male and Caucasian, with less than half aware that the NCAA had made Hb AS testing 
mandatory for Division I athletes.  The authors found that mandatory screening was 
not supported as a whole, but that many preferred screening based on type of sport 
played and race/ethnicity.  Some participants expressed worry that carriers would 
face discrimination of some kind based on their status.  Only 42% respondents felt 
that college level athletes would face discrimination, 38% felt professional athletes 
would face it, and 43% and 49% felt carriers would face discrimination through health 
insurance or life insurance respectively.  Seventy-five percent of the pediatricians felt 
that the athlete or his/her parents should be allowed to sign a waiver in order to 
decline screening (Koopsmans et al, 2011).   
 A similar study among sports medicine providers found that 90% of the 
respondents were aware of the testing policy. Forty-one percent were in favor of 
screening all athletes for Hb AS while 76% supported selective screening based on 
race/ethnicity.  Male physicians favored selective screening more than female 
physicians.  The majority of participants felt the athlete or his or her parent should 
be able to opt of the screening program.  Twenty-five percent of respondents felt the 
athlete would face discrimination at all playing levels, while 40% felt it was a 
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possibility.  Rates were similar among physicians regarding insurance discrimination 
with 37% feeling they would definitely be discriminated against and 41% feeling they 
might be in regards to health insurance, and 39% thinking they would definitely face 
discrimination, and 42% thinking they may face discrimination in obtaining life 
insurance (Achaya et al., 2011). 
Guidelines for Prevention & Treatment of Exertional Sickling 
  The National Athletic Trainer’s Association (NATA) provides guidelines for the 
recognition and treatment of ES crises.  They suggest that all coaches, parents, and 
trainers be educated regarding signs and symptoms of ES, allowing a longer recovery 
time between conditioning repetitions and excluding Hb AS athletes from 
performance tests based on environmental and physical factors.  In addition, they 
suggest placing an emphasis on adequate hydration, refraining from exercise if the 
athlete is ill, controlling asthma, and adjusting work-rest cycles based on 
environmental heat stress.  Upon presentation of an ES they recommend immediate 
removal from the activity, administration of high flow oxygen, cooling the athlete, 
and the monitoring of vital signs.  They also suggest having emergency equipment on 
hand to deal with explosive rhabdomyolysis and its associated metabolic 
complications.  NATA lists differences between ES and HI, that include muscle 
twinges, excruciating and specific pain, and contracted and hard muscles in HI, 
compared to no twinges, generalized pain, muscle weakness, and normal muscle 
presentation in ES (Anderson et al., 2012). 
 Sickle cell trait testing in athletes faces many challenges. It is controversial, 
tests can be inaccurate and expensive, risks are not clearly relayed to carriers, many 
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students choose not to participate, and the risk of discrimination of any kind against 
carriers is high.  Medical care providers, coaches, trainers, Hb AS athletes, and the 
athletes’ families face a difficult ethical dilemma:  does the risk of discrimination 
outweigh the price of 1 life saved?  Guidelines regarding prevention and treatment of 
ES may help reduce the risk of sickling crises among athletes, but guidelines are not 
enforceable.  A more complete understanding of the genetic and environmental 
factors that precipitate sickling crises is crucial in the effort to protect Hb AS 
individuals while maintaining their privacy and respecting their personal choices.   
Suggestions for Education and Medical Treatment of Hb AS Individuals 
 No evidence exists regarding treatment to increase standing Hb F levels among 
Hb AS carriers.  As Hb AS is often a benign mutation no clinical trials have been 
conducted to examine the use of neoplastic drugs such as hydroxyurea.  These drugs 
can cause severe side effects so their use on those who have historically been 
considered healthy individuals has not been warranted.  However, new evidence 
suggesting that not all Hb AS carriers have a favorable clinical course may someday 
prompt the study of preventative treatment, which may include increasing Hb F 
levels.  Additionally, given the controversy surrounding mandatory testing for Hb AS it 
is highly probably that arguments surrounding the testing and use of drugs that may 
enhance the performance of Hb AS athletes will arise.  Overall, the author feels that 
it is not appropriate to investigate the use of drugs that increase Hb F levels on Hb AS 
carriers until we better understand the risk factors and causes for their health 
disparities.       
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 Public health campaigns to educate Hb AS carriers and medical care providers 
about their mutation and its potential for ill health are justified at this time.  
Educating medical care providers about the possibility for adverse clinical courses in 
Hb AS carriers will help providers administer appropriate care.  Campaigns could also 
be used to encourage providers to appropriately educate carriers and their families so 
that they better understand the potential health risks.   
Newborn screening panels test for sickle cell disease, and sickle cell trait by 
proxy, in 41 U.S. states and also the District of Columbia (Lane, 2001).  Despite this 
mandatory testing, many Hb AS carriers do not know that they carry the gene.  This 
may due to a lack of communication between health care professionals and parents or 
parents and children as it is generally thought not to cause health problems.   Thus, 
further studies examining the attitudes surrounding Hb AS in health care professionals 
and those with SCD or Hb AS should be conducted.  Broadly, future investigations 
should examine the delivery method of testing results to care providers, if and how 
these providers convey results to parents, whether providers believe these results are 
medically important, why they do or do not inform parents of the results, and how 
parents interpret and treat these results.  Challenging and changing beliefs about the 
Hb AS mutation and health are important in the effort to promote practices 
supporting the overall wellbeing of individuals who carry Hb AS.     
Recruitment Difficulties 
 This study faced a number of limitations.  First and foremost was the incredible 
difficulty found in recruiting participants.  Student athletes are a particularly well-
protected group of athletes who are held to privacy standards above and beyond 
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normal college students.  Often, their schools control their use of personal media as it 
can directly reflect on the school itself (Yuksel, 2012).  As such, it is impossible to 
contact student athletes directly.  In fact, the author was only able to speak with 1 
student athlete directly and he attended her university.  He did not, however, 
actually participate in the study.  These programs and students are so well shielded 
that the author was unable to gain access to a football practice at her own university 
in order to observe the types of conditioning drills associated with football practice 
despite multiple attempts on her behalf by a team physician.   
 In addition to these issues, more than 1 athletic trainer informed the author 
that Hb AS athletes often do not understand the medical implications of their carrier 
status; some athletes are not even aware that it is a genetic condition and have asked 
if they must be retested year after year.  Also, student athletes generally lead rather 
busy lives between training and attending college and many did not have the time to 
participate.  Additionally, the author was surprised to learn that the athletes had the 
option to sign a waiver and not participate in the screening program.  It came to light 
that many athletic trainers and coaches have their entire team sign the waiver and no 
Hb AS testing is performed for that college or university (Anonymous, 2013).   
Limitations 
 Selection and information biases were present in this study.  Volunteer bias 
was a large concern to this study since it was difficult to recruit participants and 
seems likely that those who were willing to participate did so for reasons known only 
to themselves.  Participants in this study may differ from participants who were not 
eligible for inclusion based on important variables such as participation in organized 
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sports.  Participants in this study also represent a very healthy segment of the Hb AS 
population and may not accurately represent all Hb AS symptoms and health 
outcomes.  Consent bias is possible, as a number of potential participants received 
participation kits, but chose not to participate.  Bias was also evident from missing 
data as many participants did not answer all questions on their surveys.  Additionally, 
the study may not be an accurate representation of the available literature since 
articles were only reviewed if they had been published in English.     
 Information bias was present in the forms of recall and social desirability 
biases.  Participants were likely to answer questions in a way that minimized adverse 
health events in order to protect their student athlete status.  They also may not 
accurately recall adverse clinical outcomes that happened many years prior to 
participation and may not have been diagnosed correctly, if at all, at that time.   
Strengths 
 This study benefitted from the possible inclusion of all Hb AS collegiate football 
players regardless of age, race, and location.  
Phase 2 – Expected Results 
 Phase 2 of this study is expected to both increase the sample and to return 
results on SNPs associated with increased levels of Hb F as well as sickle haplotype.  
This data will be used to determine whether or not there is an association between 
Hb F levels, haplotype, and adverse health outcomes.  We hypothesize that SNPs 
associated with worse clinical outcomes in SCD individuals are those carried by Hb AS 
individuals who experience poor health.   
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Conclusion 
 
 The sickle mutation can cause mild to severe ill health among Hb SS and Hb AS 
individuals.  Sickle cell trait is associated with increased risk of exertional sickling and 
death in individuals performing intense physical exercise.  Although other 
environmental, genetic, and hemorheological characteristics influence the extent and 
severity of the sickling crisis, Hb AS is nonetheless a risk factor for adverse clinical 
outcomes.  High levels of Hb F in circulating erythrocytes may mitigate the extent of 
the sickling crisis since Hb F is resistant to polymerization.  Guidelines to help prevent 
sickling crises have been produced, but it is not possible to ensure that they are 
enforced.   
 The risk of sudden death among Hb AS individuals has been overlooked and 
underestimated.  That any sudden deaths should occur in athletes in peak physical 
condition during the prime of their lives is alarming.  Efforts to prevent these deaths 
through education and research has waxed and waned since the 1970’s, resulting in a 
poorly understood set of clinical variables that affect the occurrence of exertional 
sickling.  New research into genetic modifiers that result in higher than normal Hb F 
levels has offered renewed hope into the study Hb SS and Hb AS health outcomes, but 
has not progressed to the point where it can be used to alleviate symptoms.  The 
research presented herein, and the research that will be undertaken in the second 
phase of this study has the potential to benefit a neglected group of individuals.  The 
results of this study may ultimately help health care providers, coaches, athletic 
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trainers, and Hb AS individuals understand why some present with mild to severe 
health events while others do not.  This information may also be used to create more 
detailed guidelines regarding health risks and prevention in Hb AS carriers. 
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Abbreviation Meaning
AA African Americans
ACS Acute Chest Syndrome
ALHY Adequate Level of Hydration
CAR Central African Republic
COD Cause of Death
COMPMPD Muslce Pain Duration in Comparison with Peers
COMPPN Muscle Pain Severity in Comparison with Peers
COMPRECV Recovery Time in Comparison with Peers
CSSCD Cooperative Study of Sickle Cell Disease
CVA Cerebrovascular Accident
DNA Deoxyribonucleic Acid
ES Exertional Sickling
FCP F Cell Production Locus
Hb A Alpha Hemoglobin Chains
Hb AA Normal Adult Hemoglobin
Hb AS Sickle Cell Trait Hemoglobin
Hb B Beta Hemoglobin Chains 
Hb D Minor Delta Hemoglobin
Hb F Fetal Hemoglobin
Hb G Gamma Hemoglobin
Hb SS SickleCell Hemoglobin
HBCUs Historically Black Colleges and Universities
HCM Hypertrophic Cardiomyopathy
HI Heat Illness
HPFH Hereditary Persistence of Fetal Hemoglobin
HU Hydroxyurea
ICD International Classification of Diseases Index
MCV Mean Corpuscual Volume 
MHIF Minneapolis Heart Institute Foundation
NATA National Athletic Trainer's Association
NCAA National Collegiate Athletic Association
NCCSIR National Center for Catastrophic Sports Injury Research
NHBLI National Heart, Lung, and Blood Institute
NICHHD National Institute of Child Health and Human Development
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PHW Parent Heart Watch
RFLP Restriction Fragment Length Polymorphism
SAI Saudi Arabia/Indian Haplotype
SCD Sickle Cell Disease
SHEMC School of Human Evolution & Molecular Change
SHLHY Safe and Healthy Level of Hydration
SIT Silent Infarct Transfusion
SNPs Single Nucleotide Polymorphisms
U.K. United Kingdom
U.S. United States
UD Unhealthy Dehydration
VOC Vaso-occlusive Crisis
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Appendix 3. Carriers of Sickle Cell Trait – Facebook page  
 
Carriers of Sickle Cell Trait:  
 
https://www.facebook.com/pages/Carriers-of-Sickle-Cell-Trait/150929204998069 
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Appendix 4. Sickle Cell Trait in Athletes Survey 
 
Sickle Cell Trait in Athletes 
 
 
 
 
 
 
Please give us your contact information so that we can contact you if we need to: 
 
First Name               Last Name                       
 
Date of Birth (mm/dd/yyyy):             /           /       
 
Mailing Address:              
 
City                State           Zip Code     
 
E-mail:         
 
Phone Number With Area Code: (        )     
 
 
 
This survey has five sections.  Each section will have instructions on how to answer the 
questions in that section.  Throughout this survey sickle cell trait is referred to as HB AS. The 
survey should take approximately 15-30 minutes to complete. If you have any questions please 
call 802.585.1054 and ask for Carroll Flansburg. Your answers will be kept private and you will 
not be identified in our study. 
 
 
 
Thank you for your participation in this study! With your help we  
hope to be able to allow athletes like yourself to make  
more informed health decisions. 
 
 
 
YOU CAN ONLY TAKE PART IN THIS STUDY IF  
YOU HAVE HAD A BLOOD TEST AND BEEN  
TOLD BY A MEDICAL PROFESSIONAL  
THAT YOU CARRY SICKLE CELL TRAIT 
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Go	  to	  Q2	  
	  
Describe	  your	  symptoms	  in	  the	  space	  below.	  
Skip	  to	  Section	  II	  	  
Section I - Your Experience(s) with Dehydration: 
 
Q1. Have you ever felt unusually dehydrated? Place a ✓ or an X in the box next to your  
       answers.    
 
Yes…………………………………………………………………..…………..…1 
No…………………………………………………………….……………….…….2 
Prefer not to answer………...……………………...……….......88 
Do not know……………….………………………………………………..99 
 
Q2.  If yes to Q1, place a ✓ or an X in the box next to your symptoms. You may mark as many  
        as you need to. 
 
Dry, sticky mouth…...…………………………………………………….......1  
Sleepiness or tired.…………………………………………………............2 
Thirst/Extreme Thirst.….………………………………………………..…...3 
Decreased urine output……..………………...….…………..……….....4 
Headache…………...…………………………………………………………….....5 
Dizziness or lightheadedness……………….………………………........6 
Lack of sweating……………………………………………….………………..…7 
Rapid Breathing …………………………………………………...……………..8 
Low Blood Pressure……………………………………..……………….......9  
Rapid Heartbeat ……………………………………………………..….......10 
Dry skin that doesn’t “bounce back” when pinched………...11 
Prefer not to answer…………………………………………………………..88 
Do not know………………………………...…………………………………….99 
Other………………………………………………………………………….……….12 
    
    If “other” please describe your symptoms here: 
               
                 
 
Q3.  Please write the number of times you have experienced these symptoms:    
 
Q4.  Please list the name of the city and the state where you experienced these symptoms.    
        If it has happened more than once please list all locations by city and state. Place a ✓ or  
        an X in the box next to your answers if you don’t know or would prefer not to answer. 
 
Do not know…………………………………………….…………………….…..88  
Prefer not to answer…………………………………………..………......99 
  
City            State      
City            State      
City            State      
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Go	  to	  Q8	  Skip	  to	  Section	  V	  
Q5. Do you feel that you keep a safe and healthy level of hydration during training (do  
       you drink enough liquids to stay healthy)? Place a ✓ or an X in the box next to your  
       answers.   
   
Yes.………………………………………………………...……...............................1   
No………………………………………………………………………............................2 
Prefer not to answer………………………………………..………………………………..88 
Do not know…………………………………………………..…………....................99 
 
 
Q6. Do you feel that you keep an adequate level of hydration during athletic competitions (do  
       you drink enough liquids to stay healthy)? Place a ✓ or an X in the box next to your  
       answers. 
 
Yes.………………………………………………………...……...............................1   
No………………………………………………………………………............................2 
Prefer not to answer………………………………………..………………………………..88 
Do not know…………………………………………………..…………....................99 
 
 
Section II: Your Experience(s) with Heat Illness Diagnoses: 
 
Q7. Have you ever been told you had “heat illness” by the athletic department staff or medical  
       personnel? Place a ✓ or an X in the box next to your answers. If you mark “no”, “prefer  
       not to answer”, or “don’t know” please skip to Section III.  
     
Yes.………………………………………………………...……...............................1    
No………………………………………………………………………............................2 
Prefer not to answer………………………………………..………………………………..88 
Do not know…………………………………………………..…………....................99 
 
  
Q8. If you marked “yes” to Q7, please tell us at what point in the season you were diagnosed  
       with “heat illness”. Please note, we are NOT asking about off-season training. Place a ✓ or    
       an X in the box to mark your answer. You may mark more than one box if you need to. 
 
Yes.………………………………………………………...……...............................1    
No………………………………………………………………………............................2 
Prefer not to answer………………………………………..………………………………..88 
Do not know…………………………………………………..…………....................99 
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Q9. What was the intensity of your work out right before you were diagnosed with “heat  
        illness”? Place a ✓ or an X in the box next to your answers. You may mark more than one  
        box if you need to. 
 
No exertion at all……………………………………………………….…….............1 
Extremely light………………………………………………..……………...............2 
Very light………………………………………………………..……….……………………….3 
Light………………………………………………………………..………………………………..4 
Somewhat hard………………………………………….………………..................5 
Hard……………………………………………………………….………………...............6 
Very hard……………………………………………………..…………………..............7 
Extremely hard…………………………………………..…………………………………….8 
Maximal exertion…………………………………….………………………..............9 
Prefer not to answer……………………………………………………...............88 
Do not know…………………………………………………………………………………….99 
 
Q10. If you were told you had “heat illness” by the athletic department staff or medical  
         personnel please place a ✓ or an X in the box next to your symptoms. Please mark all of      
         your symptoms. 
 
Hard, tense muscles…………………………………………………………………..….1 
Fatigue……………………………………………………………………………............2 
Nausea and/or vomiting………………………………………………….…………….3 
Headaches……………………………………………………………….……...…………..4 
Excessive Thirst………………………………………….……………………...........5 
Fainting………………………………………………………..…………………...........6 
Agitation……………………………………………………..………………………………..7  
Weakness………………………………………………….……………………............8 
Confusion or anxiety…………………………………………..………….….........9 
Hot, flushed or dry skin…………………………………...………………………..10 
Decreased sweating…………………………………….……………………………….11 
Breathlessness……………………………………………………………………………….12 
Lower amounts of urine…….…………………...……………………………………13 
Blood in urine or stool…………………………….………………………...........14 
Increased body temperature……………………………………………...........15 
Convulsions or seizures…………………………………….…………………………..16 
Confusion……………………………………………………………..…………...........17 
Heat cramps that are severe or sometimes disabling…………………..18 
Drenching sweats…………………………………………………………….............19  
Cold and clammy skin…………………………..………………………………………..20 
Prefer not to answer………………………….…………………………………………..88 
Do not know…………………………………………………………………….............99 
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Go	  to	  Q15	  Skip	  to	  Section	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Q11. Please list the name of the city and the state where you were when you were diagnosed  
         with “heat illness”. If it has happened more than once please list all locations by city and  
         state. Place a ✓ or an X in the box next to your answers if you would prefer not to answer  
         or do not know. 
 
Prefer not to answer……………………………………………….……………..…….99   
Do not know……..…….………………………………………..…..………...........88 
  
City            State      
City            State      
City            State      
  
 
Section IV - Your Workouts: 
 
Q12. Compared with your teammates, do you feel that your muscle pain lasts for longer  
          periods of time? Place a ✓ or an X in the box next to your answer. 
 
Yes.………………………………………………………...……...............................1    
No………………………………………………………………………............................2 
Prefer not to answer………………………………………..………………………………..88 
Do not know…………………………………………………..…………....................99 
 
Q13. Compared with your teammates, do you feel that your muscles take longer  
         to recover from workouts or training? Place a ✓ or an X in the box next to your answer. 
 
 
Yes.………………………………………………………...……...............................1    
No………………………………………………………………………............................2 
Prefer not to answer………………………………………..………………………………..88 
Do not know…………………………………………………..…………....................99 
 
Q14. Compared to your teammates, do you feel that you experience high amounts of muscular  
         pain? Place a ✓ or an X in the box next to your answer. 
  
Yes…………………………………………………………………………………………………………1  
No………………………………………………………………………………………...............2 
Prefer not to answer……………………………………….…………………………………88 
Do not know……………………………………………………………………...............99 
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Skip	  to	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Go	  to	  Q17	  
 
Q15. If you marked “yes” to Q14, please tell us how severe your pain was. Place a ✓ or an X  
         in the box next to your answer.  
 
Mild………………………………………………..…………………………….…………...……...1 
Moderate…………………………………….………………………….………………….….....2 
Severe…………………………………..……………………………………………..…….......3 
Causes you to be unable to perform normal activities……………….…….4 
Prefer not to answer………………………..…………………...……………..……….88 
Do not know………………………………….………………..……………………………...99 
 
Section V – Your Experiences with Exertional Sickling:  
 
Q16. Have you ever been told you had “exertional sickling” by the athletic department staff or  
         medical personnel? Place a ✓ or an X in the box next to your answer. 
 
Yes.…………………………………………………………………….……………..………...1 
No.…………………………………………………………………….…………..……….…...2 
Prefer not to answer……………………………………………….……………………88 
Do not know………………………………………..…………………..………………...99 
 
Q17. If you answered yes to Q16 please place a ✓ or an X in the box next to your symptoms.  
         Please mark all your symptoms. 
 
Leg pain or weakness……………………………..…….…….……………………......1 
Low back pain or weakness……………………………..…..………..……………...2 
Muscle cramping that spread throughout the body…………..……...……3 
Rapid breathing……………………………………………………......................4 
 Prefer not to answer………………………………………………….…………………..88 
 Do not know…………………………………………………………………….............99 
 
Q18.  Please write the number of times you have experienced these symptoms:   
 
Q19. Where were you when you were diagnosed with “exertional sickling”? Please list the  
          name of the city and the state. If it has happened more than once please list all 
locations  
          by city and state. Place a ✓ or an X in the box next to your answers if you don’t know or  
          would prefer not to answer. 
 
Prefer not to answer……………………………………………...….…................88   
Do not know…….……………………………………………………………………..…….....99 
  
City            State      
City            State      
City            State      
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Section VI – Your Background Information: 
 
Q20. How much do you currently weigh in pounds?    lbs                                                                                                                   
 
Q21. What is your height? ft                                                   
 
Q22. Do you smoke? Place a ✓ or an X in the box to mark your answer. 
   
Yes..………………………….……………………………………………….…………………..1 
No…..…………………………………………………………………….…………………..…..2 
Prefer not to answer………….………………………………………………………….88 
Do not know……………………………………………………..………...…...........99 
 
Q23. Do you have asthma? Place a ✓ or an X in the box to mark your answer. 
 
Yes..………………………….…………………………………………..…………………………1  
No…..…………………………………………………………………..…………………..……..2 
Prefer not to answer………….………………………………………………..………..88 
Do not know………………………………………………..…………………….……......99 
 
Q24. What position do you play on your football team? Place a ✓ or an X in the box to mark  
         your answer. You may mark all that apply. 
 
Safety………………………………………..…………………..……………………………......1 
Cornerback……………………………………………….……………………………......…….2 
Outside Linebacker………………………….……………..……………….…...…….....3 
Defensive End………………………………..……………......................……....4 
Defensive Tackle…………………………………..………………………….…....……....5 
Middle Linebacker………………………………….……………………..………..……....6 
Wide Receiver……………………………………………………...……..………….……....7 
Offensive Tackle……………………………………………….…….…………….....…....8 
Offensive Guard……………………………..…………….…….………………...….......9 
Center……………………………………………….………………….………………....…....10 
Tight End………………………………………………………..………………………….......11 
Quarterback…………………………………………………..………………………...…....12 
Fullback/Running Back……………………….……………………...………..........13 
Halfback/Running Back…………………………….……………………………...…….14 
Prefer not to answer………………………….……………………………...…........88 
Do not know………………………………………..……………………………...….......99 
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Q25. If you know anything about the background of your biological family, please tell us  
         where they came from. Place a ✓ or an X in the box to mark your answer. You may mark  
         all that apply.   
 
Northern Europe………………………………………………………..……………………..............1 
Southern Europe……………………………………………………….……………………….……..……..2 
Middle East and North Africa………………………………..………………..……...............3 
Pre-partition India (Sri-Lanka, India, Pakistan, Tibet)…..............…...........4 
South East Asia (Thailand, Vietnam, etc.)………………………………………...……………5 
China………………………………………….......................................................6 
Central and Eastern Europe (including all former Soviet republics)……………...7 
Melanesia, Micronesia, Polynesia and Australia……………………………………….…..…8 
Latin American of African descent………………………………………………………..…………9 
Latin American of Amerindian descent……………………………………….……..…………10 
Latin American of Northern European descent…………………….……….………………11 
Latin American of Southern European descent……………………….………………….…12 
North American of Amerindian descent…………………………………………………....…13 
North American of Northern European descent…………………..……………………...14 
North American of Southern European descent…………………………………..……...15 
North American of African descent……………………………………………………….……..16 
Caribbean of African descent……………………………………………………..….…………...17 
Caribbean of Amerindian descent……………………………………………….…………………18 
Caribbean of Northern European descent………………………………….………………….19 
Caribbean of Southern European descent……………………………….…………………….20 
Caribbean of East Asian descent………………………………………….………………………..21 
Prefer not to answer……………………………............................................88 
      Do not know……………………………………………………………………..………….……………….99 
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Go	  to	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Q26. How do you identify yourself? Place a ✓ or an X in the box to mark your answer. You  
         may mark all that apply.   
 
Hispanic, Latino, or Spanish origin…………………………………………………....1 
Mexican, Mexican American, or Chicano…………………......…………….....2 
Puerto Rican…………………………………..........................................3 
Cuban……………………………….………………………………………………....…….......4 
White………………………………………………..…………………………….……...…………5 
Black, African American, or Negro…….…………….………....................6 
American Indian or Alaska Native……………………….……………………………..7 
Asian Indian………………………………………………………..........................8 
Japanese…………………………………………….…………………………….…….........9 
Native Hawaiian………………..…………………………………………………………….10 
Chinese………………………...…………………………...………………….............11 
Korean………………………...………………………………………………………………….12 
Guamanian or Chamorro……………..………………….........................13 
Filipino………………………...……………………..…………….......................14 
Vietnamese…………………...…………………….………………………………………….15 
Samoan……………………...……………………………...…………………..............16 
Other Asian………………...…………………………………………..………………………17 
Other Pacific Islander……...………………………………………………............18 
Prefer not to Answer……...……………………………………………………………….88 
Do not know……………...…………………………………………...………………......99 
 
Q27. Do you have any other blood disorders besides Sickle Cell Trait? (An example of another  
         blood disorder is a thalassemia.) Answer “yes” ONLY if you have had a blood test and  
         been told that you do have another blood disorder. Answer “no” only if you do not know  
         if you have had any such blood tests and you do not know if you do or do not carry any  
         of these disorders. Place a ✓ or an X in the box to mark your answer. 
 
Yes……………………………..…………………………………….……………………..…...….1 
No……………………………………………………………….…...…...………………….......2 
Prefer not to answer……….…………………....................................88 
Do not know…………………………………………………..………………………………….99 
 
Q28. If yes, what blood disorder besides Sickle Cell Trait do you have?     
 
 
Q29. Average resting blood pressure (please leave blank if you do not know): 
  
   /   
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Describe	  your	  symptoms	  in	  the	  space	  below.	  
Section VII: Your Experiences with Ill Health During Training or Workouts: 
 
Q30. Please mark all symptoms you have experienced during training or workouts. Place a  
         ✓ or an X in the box next to your answer. You may mark all that apply.  
 
Dry, sticky mouth…...…………………………………………………………..............1  
Sleepiness or tiredness.……………………………………............................2 
Thirst/Extreme Thirst.….………………………………………........................3 
Decreased urine output……..………………...….……………......................4 
Headache…………...…………………………………………..............................5 
Dizziness or lightheadedness……………….………………….......................6 
Rapid Breathing ………………………………………...………….…....................7 
Low Blood Pressure………………………………………………........................8 
Rapid Heartbeat …………………………………………………….......................9 
Dry skin that doesn’t “bounce back” when pinched…...................10 
Hard, tense muscles……………………………………………...…………………………..11 
Fatigue………………………………………………………………...….....................12 
Nausea and/or vomiting………………….……………………………………………...…13 
Headaches……………………………………………...………………………………………….14 
Fainting………………………………………………….………………......................15 
Agitation……………………………………………………………………………….…………….16 
Weakness…………………………………………………………………………………….......17 
Confusion or anxiety……………………………………………………….………….……..18 
Hot, flushed or dry skin…………………………………………………..…………......19 
Decreased sweating…………………………………………….………………………...….20 
Breathlessness………………………………………………….…………………………...….21 
Lower amounts of urine…….……………………………………..………………...….22 
Blood in urine or stool………………………………..…………………………….......23 
Increased body temperature………….…………………………………..…….......24 
Convulsions or seizures…………………………..………………………….……...…..25 
Heat cramps that are severe or sometimes disabling..……………….…..26 
Drenching sweats………………..………………………………................….....27  
Cold and clammy skin…………………………………………..…………………….…...28 
Leg pain or weakness………………………….………………………………….........29 
Low back pain or weakness………………………..……………………….…...…...30 
Muscle cramping that spread throughout the bod.………………..….....31 
           Prefer not to answer………………………………………….…………………..……...88 
Do not know…………………………………………….………...……………….….…....99 
Other…………………………………………………….……………………………………...…32 
 
  If “other” please describe your symptoms here: 
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Q31. Where were you when you experienced these symptoms? Please list the name of the city  
          and the state. If it has happened more than once please list all locations by city and 
state. Place a ✓ or an X in the box next to your answers if you don’t know or would 
prefer not to answer. 
 
Prefer not to answer……………………………………..….…………….…….........88   
Do not know…….……………………………………………………..……………...….....99 
  
City            State      
City            State      
City            State      
 
 
    
 
 
 
 
 
                 THANK YOU FOR YOUR PARTICIPATION! 
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Appendix 5. SAS Code 
 
libname HB AS "s:\HB AS"; 
proc import datafile = 's:\HB AS\HB ASDatacopy.xls' 
DBMS = xls OUT = HB ASData; 
run; 
 
/*Missing Value Counts*/   
 
proc means data=HB ASData nmiss n; 
run;  
 
/*Contents*/ 
 
proc contents data=HB ASData; 
run; 
 
/*Fisher’s Exact Tests*/ 
 
data fisher;  
input UNDHY EXSCKL count;  
datalines;  
1 1 2  
1 0 10  
0 1 3  
0 0 5  
;  
run; 
 
proc freq data=fisher order=data;  
weight count;  
tables UNDHY*EXSCKL;  
exact fisher; 
run; 
 
 
data fisher1;  
input UNDHY DHI count;  
datalines;  
1 1 1  
1 0 10  
0 1 1  
0 0 7  
;  
run; 
 
proc freq data=fisher1 order=data;  
weight count;  
tables UNDHY*DHI;  
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exact fisher; 
run; 
 
data fisher2;  
input DHI EXSCKL count;  
datalines;  
1 1 1  
1 0 1  
0 1 4  
0 0 13  
;  
run; 
 
proc freq data=fisher2 order=data;  
weight count;  
tables DHI*EXSCKL;  
exact fisher; 
run; 
 
data fisher3;  
input COMPMPD UNDHY count;  
datalines;  
1 1 2  
1 0 0  
0 1 9  
0 0 6  
;  
run; 
 
proc freq data=fisher3 order=data;  
weight count;  
tables COMPMPD*UNDHY;  
exact fisher; 
run; 
 
data fisher4;  
input COMPRECV UNDHY count;  
datalines;  
1 1 4  
1 0 0  
0 1 7  
0 0 5  
;  
run; 
 
proc freq data=fisher4 order=data;  
weight count;  
tables COMPRECV*UNDHY;  
exact fisher; 
run; 
 
data fisher5;  
input COMPPN UNDHY count;  
datalines;  
1 1 2  
1 0 0  
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0 1 7  
0 0 6  
;  
run; 
 
proc freq data=fisher5 order=data;  
weight count;  
tables COMPPN*UNDHY;  
exact fisher; 
run; 
 
data fisher6;  
input COMPRECV COMPMPD count;  
datalines;  
1 1 4  
1 0 2  
0 1 0  
0 0 12  
;  
run; 
 
proc freq data=fisher6 order=data;  
weight count;  
tables COMPRECV*COMPMPD;  
exact fisher; 
run; 
 
data fisher7;  
input COMPPN COMPMPD count;  
datalines;  
1 1 1  
1 0 1  
0 1 0  
0 0 13  
;  
run; 
 
proc freq data=fisher7 order=data;  
weight count;  
tables COMPPN*COMPMPD;  
exact fisher; 
run; 
 
data fisher8;  
input COMPMPD DHI count;  
datalines;  
1 1 1  
1 0 1  
0 1 1  
0 0 13  
;  
run; 
 
proc freq data=fisher8 order=data;  
weight count;  
tables COMPMPD*DHI;  
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exact fisher; 
run; 
 
data fisher9;  
input COMPRECV DHI count;  
datalines;  
1 1 1  
1 0 3  
0 1 1  
0 0 10  
;  
run; 
 
proc freq data=fisher9 order=data;  
weight count;  
tables COMPRECV*DHI;  
exact fisher; 
run; 
 
data fisher10;  
input COMPPN DHI count;  
datalines;  
1 1 0  
1 0 2  
0 1 1  
0 0 11  
;  
run; 
 
proc freq data=fisher10 order=data;  
weight count;  
tables COMPPN*DHI;  
exact fisher; 
run; 
 
data fisher11;  
input SHLHY UNDHY count;  
datalines;  
1 1 9  
1 0 5  
0 1 3  
0 0 0  
;  
run; 
 
proc freq data=fisher11 order=data;  
weight count;  
tables SHLHY*UNDHY;  
exact fisher; 
run; 
 
data fisher12;  
input ALHY UNDHY count;  
datalines;  
1 1 8  
1 0 6  
	  	  130	  
0 1 4  
0 0 0  
;  
run; 
 
proc freq data=fisher12 order=data;  
weight count;  
tables ALHY*UNDHY;  
exact fisher; 
run; 
 
data fisher13;  
input SHLHY DHI count;  
datalines;  
1 1 1  
1 0 12  
0 1 1 
0 0 2  
;  
run; 
 
proc freq data=fisher13 order=data;  
weight count;  
tables SHLHY*DHI;  
exact fisher; 
run; 
 
data fisher14;  
input ALHY UNDHY count;  
datalines;  
1 1 1  
1 0 12  
0 1 1  
0 0 3  
;  
run; 
 
proc freq data=fisher14 order=data;  
weight count;  
tables ALHY*UNDHY;  
exact fisher; 
run; 
 
data fisher15;  
input SHLHY EXSCKL count;  
datalines;  
1 1 3  
1 0 11  
0 1 1  
0 0 2  
;  
run; 
 
proc freq data=fisher15 order=data;  
weight count;  
tables SHLHY*EXSCKL;  
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exact fisher; 
run; 
 
data fisher16;  
input ALHY EXSCKL count;  
datalines;  
1 1 3  
1 0 11  
0 1 1  
0 0 3  
;  
run; 
 
proc freq data=fisher16 order=data;  
weight count;  
tables ALHY*EXSCKL;  
exact fisher; 
run; 
 
data fisher17;  
input COMPMPD EXSCKL count;  
datalines;  
1 1 0  
1 0 2  
0 1 4  
0 0 11  
;  
run; 
 
proc freq data=fisher17 order=data;  
weight count;  
tables COMPMPD*EXSCKL;  
exact fisher; 
run; 
 
data fisher18;  
input COMPRECV EXSCKL count;  
datalines;  
1 1 1  
1 0 3  
0 1 3  
0 0 9  
;  
run; 
 
proc freq data=fisher18 order=data;  
weight count;  
tables COMPRECV*EXSCKL;  
exact fisher; 
run; 
 
data fisher19;  
input COMPPN EXSCKL count;  
datalines;  
1 1 1  
1 0 1  
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0 1 3  
0 0 10  
;  
run; 
 
proc freq data=fisher19 order=data;  
weight count;  
tables COMPPN*EXSCKL;  
exact fisher; 
run; 
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